[{"article": "He then wanted to show us that radio waves are harmless to humans, and even moved his hand back and forth into the force field. \"Nothing happens,\" he told Stahl.\nDr. Curley thought there was so much promise in Kanzius' invention, he began conducting his own research with the machine, using tiny bits of gold nano-particles that are so small, thousands of them can be injected into a single cancer cell. The radio waves then heat up the gold, which kills the cancer. But Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nJohn Kanzius invented a radio wave machine that he believed would one day cure cancer. He got cancer researchers so excited, some are already testing it out on laboratory animals.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThis story stumbles badly by portraying the Kanzius device as revolutionary, when it is actually just one of many applications of well-known principles and techniques for treating cancer. For example, radiofrequency ablation (the technical term for the Kanzius approach) is already used to treat tumors in the liver and elsewhere when conventional surgery isn\u2019t a good option. Indeed, searching www.pubmed.gov for studies of radiofrequency ablation of cancer yields almost 3,000 citations. \nThe added technique of using molecules that preferentially bind to cancerous cells in order to concentrate metallic nanoparticles within tumors is common to many targeted cancer treatments.\n The story ignored vast swaths of current cancer research and treatment.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story could have put this study into the larger context of cash payments for health incentives. This has been demonstrated to work on a number of fronts, including encouraging mothers to give birth in health centers, discouraging risky sex, and smoking cessation.", "answer": 0}, {"article": "Women were a third more likely to have had their cancer missed, report the researchers in The American Journal of Gastroenterology. And general practice physicians missed cancers 60 percent more often than gastroenterologists.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that colonoscopy is the dominant screening for colon cancer.", "answer": 1}, {"article": "MRI has long been known as an effective breast cancer screening modality that offers better sensitivity than mammography and ultrasound. Currently, guidelines reserve breast MRI screening for women who have a strong family history or other specific breast cancer risk factors. MRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release establishes that the novelty of the study lies in its challenge of the conventional wisdom that supplemental MRI screening should be recommended\u00a0to high-risk women but not average-risk women.", "answer": 1}, {"article": "It has to be strong, because every time the foot strikes the ground, the plantar fascia bears the body's full weight. In high-impact activities like running, the forces even exceed the actual weight because it's so concentrated in a narrow spot where the fascia attaches to the heel bone. That's presumably why sufferers of plantar fasciitis feel the pain in the heel.\n\"Patients have to be patient,\" Duggal says. \"They have to understand that this condition unfortunately is not fully understood.\"\nDuggal is not impressed with reported success rates.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story doesn\u2019t try to oversell the novelty of shockwave therapy.", "answer": 1}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day. If that feels a little onerous, consider new findings out of Baylor College of Medicine in Houston suggesting that love of physical activity may start in the womb.\n\u201cOur study in a mouse model is important because we can take all those effects out of the equation,\u201d Waterland said. \u201cI think our results offer a very positive message. If expectant mothers know that exercise is not only good for them but also may offer lifelong benefits for their babies, I think they will be more motivated to get moving.\u201d\nObservational studies of active pregnant women and their babies have reported \u201cresults consistent with ours,\u201d Waterland said. But in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity. The Baylor scientists were able to correct for those variables.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the current study goes beyond available observational studies in humans by utilizing an experimental design in mice.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story overstates things when it quotes a researcher who says that Deplin represents \u201ca totally new way to look at depression.\u201d A brief search turned up a study that examined a different folic acid derivative (brand name\u00a0Leuvocorin) for treatment of resistant depression some 10 years ago. And several existing therapeutic approaches,\u00a0including\u00a0supplementation with omega-3 fatty acids and the amino acid SAM-e (S-adenosylmethionine), are based on the idea that individuals with\u00a0depression lack the building blocks needed to manufacture sufficient quantities of certain neurotransmitters.\u00a0The premise of these\u00a0approaches\u00a0is very\u00a0similar to that which is driving research on Deplin.", "answer": 0}, {"article": "Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society\u2019s challenges with our talented team and proven experience in global markets. The company\u2019s consolidated revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3 billion). Hitachi is focusing more than ever on the Social Innovation Business, which includes power & infrastructure systems, information & telecommunication systems, construction machinery, high functional materials & components, automotive systems, healthcare and others. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.\nTOKYO--(BUSINESS WIRE)--Hitachi, Ltd. (TSE:6501, \u201cHitachi\u201d) today announced that Johns Hopkins Medicine has selected Hitachi to provide its proton beam therapy (PBT) system at Sibley Memorial Hospital located in Washington, D.C. This collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital. This will be Hitachi\u2019s fifth PBT system in North America.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release fails on two fronts here. First, the news release claims, \u201cThis collaboration, which includes a 10-year maintenance service, marks the first multi-room PBT application in the nation\u2019s capital.\u201d The fact that this a \u201cmulti-room\u201d system is not a meaningful claim when there are other facilities under construction (at least one of which will apparently open before Sibley\u2019s) nearby. Second, the release did not meet our standard for establishing the novelty of the technology. The release states, \u201cThe proton center at Sibley Memorial Hospital will be an impressive demonstration of industry and academic medicine collaborating to bring a new technology and new cancer treatment modality to Washington, D.C. and the surrounding communities.\u201d But PBT is not a new cancer treatment modality, nor will it be new to Washington D.C.\u00a0Proton therapy has been used clinically since the mid-1950s. The first proton accelerator (cyclotron) was developed in 1932 by E. O. Lawrence and S. Livingston, and Nobel physics laureate Robert Wilson proposed using it for radiation therapy in 1946. The \u201cpassive scattering\u201d technique noted in the news release was used initially at the outset. The \u201cspot scanning\u201d technique described in the release was developed and first implemented in Switzerland during the 1990s. Most proton centers can accommodate treatment using both techniques.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear that this was a new use (treatment of osteoporosis in elderly individuals who have already sustained a hip fracture) for a treatment that has FDA approval for a slightly different application.", "answer": 1}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period. Without intervention, 80 to 90 percent of infants who are born to mothers infected with hepatitis B develop a chronic infection. The current standard of care is to provide vaccine and immune globulin to reduce transmission rates.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant:\n\u201cBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\u201d\nWhile the drug itself isn\u2019t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach.", "answer": 1}, {"article": "She is, however, quite knowledgeable about how to be safe when you\u2019re in the sun. (She\u2019s also called on Terrence Collins, the Teresa Heinz Professor of Green Chemistry at Carnegie Mellon University as a consultant to formulate her line.) Ms. Peterson has long been aware of the role that antioxidants play in protecting skin from UV damage. (A groundbreaking study in 1996 proved antioxidants like vitamins C and E can boost the efficacy of sunscreen and make skin more resistant to damage.) She even brews antioxidant-rich green tea, lets it cool and puts it in a spray bottle. \u201cI spritz my kids with it before I apply sunscreen and again after they come out of the sun,\u201d she said.\nThis information is in the early stages of transforming the category of after-sun care\u2014a category traditionally limited to aloe vera-laden moisturizers and gels that lowered the temperature of sun-parched skin but not much else. Product formulators are now seeing after-sun care as another line of defense to stop cell mutations and aging in its tracks.\nNow, a new study by Yale University cancer researchers, published this year, shows that the cell-damaging effects of ultra-violet rays may continue for some time after you seek cover. Ergo, it may be necessary to draw out the day\u2019s protective ministrations into nighttime.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article identifies a number of after-sun products and notes that the marketing of these items is spurred in part by a research article published this year.", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer. But it was unclear if that effect could be chalked up to the drugs, because the condition they are meant to treat \u2014 bone thinning, or osteoporosis \u2014 is tied to low estrogen levels, which also cuts breast cancer risk.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story made it clear that the findings are part of a series of findings, some of them contradictory, about the side benefits of different drugs for cancer prevention.", "answer": 1}, {"article": "Participants -- all of whom were between ages 20 and 40 -- had an IUD known as Mirena, which released levonorgestrel, inserted for a year. They also received monthly injections of gonadotropin-releasing hormone (GnRH), which halts estrogen production, for six months.\nThe theoretical -- but still unproven -- advantage to this new IUD method, Poynor said, is that \"there is a lower risk of systemic side effects . . . and that you may be giving higher doses of the drug directly into the uterus.\"\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that the Mirena IUD is not a new idea, but using it to treat early-stage endometrial cancer is relatively novel.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nEven when screening helps predict health problems down the road, Lauer adds, that doesn\u2019t mean treatments are necessarily beneficial.\n\u201cOverdiagnosis is threatening to become an increasingly important public health problem because of the enthusiasm for and proliferation of unproven screening tests,\u201d Lauer writes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the screening test could be deduced from the story.", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the true novelty of the approach?", "explanation": "While we were uncomfortable with this story\u2019s characterization of thermoplasty as a \"new medical breakthrough\" (for reasons discussed here), the treatment is relatively new and different from existing techniques. We don\u2019t think the story misled in this regard.\u00a0\u00a0", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day. Colic affects up to 28% of infants and has no known cause or cure.\nThe findings were published online today in Pediatrics.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story failed to mention important background here. The study reported on was actually a follow-up to a previous\u00a0open label study (the researchers knew which children were getting what treatment) conducted by these same investigators and which also found a benefit for L reuteri\u00a0on colic. The fact that this second, blinded trial has confirmed the previous\u00a0findings should increase our confidence that something real is happeneing here.\u00a0Still, as previously noted, larger, independent\u00a0studies\u00a0will be needed to\u00a0conclusively establish a benefit for probiotics on colic. \u00a0\u00a0", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nJust because the system produced strong results in mice does not mean people will respond the same way. But experts say the findings provide hope for future treatments for people.\nMost of these other companies are taking a different approach from the work done in the studies published Monday.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "News stories often don\u2019t address the novelty of a treatment or research finding. But this story actually uses the word \u201cnovel,\u201d which sort of puts a spotlight on the category for us. The story quotes one of the study\u2019s funders calling the protective cell bubbles studied in the research \u201cnovel materials.\u201d We think the story actually does establish their novelty with enough context and caveats.", "answer": 1}, {"article": "This condition, known as asymptomatic carotid stenosis, is caused by plaque build-up in the arteries that carry blood from the heart to the brain. This can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\nWEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nWhen treating asymptomatic carotid stenosis, Marquardt doesn't think the case has been made for distinguishing between high- and low-risk patients. Right now, the work done by Topakian's group is still \"experimental,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is really not clear from this story whether the 2 ultrasound techniques are new, are currently in use for other applications, are both in use for visualizing carotids but are not usually used in combination as in the study.\u00a0 Is this something new or not?", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentioned that the results of this study were not novel and built on existing research.", "answer": 1}, {"article": "We Move has more about Huntington's disease.\nOne U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.\nAfter six months of treatment, patients taking the higher dose of pridopidine showed improvements in motor function -- specifically in eye and hand movements, involuntary muscle contractions (dystonia), and gait and balance -- compared with patients taking the placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Pridopidine is an experimental drug candidate for Huntington\u2019s disease and has been in clinical trials for the past several years.", "answer": 1}, {"article": "Some experts believe that gut bacteria influence the brain (and vice versa) mainly through systemic inflammation. But in this study, the researchers found no difference in inflammatory markers between the probiotic and the placebo group. McIntyre points out that the bowel communicates with the brain through other pathways as well, including the metabolic and nervous systems.\nMORE: You Asked: Should I Take Probiotics?\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression. They were followed for 10 weeks; half took a daily dose of the probiotic , and half took a placebo. The probiotics were manufactured and provided by Nestle, which also funded the study. (Nestle was not involved in collection, analysis or interpretation of study data.)\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of establishing where\u00a0the true novelty of the research lies, which is in the study population used (individuals without IBS and depression or anxiety).", "answer": 1}, {"article": "In the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges previous research that had linked high selenium with higher cholesterol levels.", "answer": 1}, {"article": "Studies suggest that ozone therapy works by reducing inflammation, shrinking herniated discs, and relieving pressure on the nerves bringing pain signals to the brain. The steroid further reduces inflammation.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD. Before the treatment, patients had tried everything without success and were considering an operation, he says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story made clear that this is a relatively new experimental approach for a disc herniation.", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story states that the device is the first medical device for obesity approved by the FDA since 2007.", "answer": 1}, {"article": "One is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what appears to be novel about this drug compared with others that reduce amyloid plaques.\nOne is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut while the story is clear that the new paper is presenting details of research first reported last year, it doesn\u2019t explain why the results are now \u201cremarkable\u201d whereas last year they were considered \u201cdisappointing,\u201d\u00a0\u201cmixed\u201d\u00a0and a \u201csetback.\u201d\nWe\u2019ll rate this a borderline Satisfactory.", "answer": 1}, {"article": "Some experts contend that allergists resist blood testing in part to protect their revenue. \u201cA barrier to allergy testing in the states has been the economics in our system,\u201d said Dr. Richard G. Roberts, professor of family medicine at the University of Wisconsin School of Medicine and Public Health. If an allergist does an in-office skin-prick test, he gets the fees for those tests. If he requests a blood test, the laboratory gets the fee.\nSkin testing produces an answer in about 20 minutes, compared with 48 hours for a blood test. The quick turnaround allows doctors to offer a diagnosis and immediate advice.\nDr. Mitchell, the Manhattan allergist, called that approach promising. \u201cA lot of academic allergists are very conservative,\u201d he said. \u201cBut Hugh Sampson\u2019s work may turn the tide.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the blood tests were developed in the 1970s but that newer tests have become available more recently.", "answer": 1}, {"article": "Hagan had some suggestions, too. \u201cSimple things like thinking about what you\u2019re grateful for every day or writing down what things make you happy or what things you\u2019re looking forward to can help someone to increase their optimism, which can improve health outcomes as we\u2019ve seen here,\u201d she said.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News. \u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\u201cSo it could be that optimism directly impacts our biological functioning,\u201d Hagan said. \u201cOptimism is linked with lower inflammation and healthier biomarker levels and lipid levels, so there could be an independent effect on optimism.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0explains what\u2019s novel here is how the research looks at all-cause mortality vs specific health behaviors and outcomes. This is established with this statement:\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News. \u201cSo in our study we wanted to expand that and look at all-cause mortality\u00a0and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d", "answer": 1}, {"article": "This week, Novartis signed a deal to have Roche unit Foundation Medicine provide genomic profiling of patient samples taken from Novartis\u2019 clinical oncology trials. Other cancer drugmakers like Bristol-Myers Squibb and Merck also have Foundation deals.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\n\u201cPIK3CA mutations are present in many other tumor types,\u201d Hirawat said. \u201cThere is a larger program we are putting into place.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn\u2013via the lead researcher\u2013that this trial provides the \u201cmost encouraging\u201d results to date in a study looking at a PI3K inhibitor in breast cancer. That establishes novelty, but we think the story should have sought independent expert viewpoint to provide context on the limitations of the results, which were based on progression-free survival and not overall survival.\nIt does not include the information that one other PI3K inhibitor is currently on the market and used to treat a type of lymphoma.", "answer": 1}, {"article": "In people with osteoarthritis, the cartilage in a joint wears away in some areas. The function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\" The wearing away of cartilage leads to pain and other symptoms.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C. He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Because the story explained that a form of strontium is available as a prescription drug for osteoporosis in several countries and because it is clear that the study in question is about a new use for this medication, we\u2019ll give the story the benefit of the doubt \u2013 even though it could have explained better that the idea that strontium ranelate can be effective for osteoarthritis is not entirely new. In studies of women taking the drug for osteoporosis, the drug seemed to have a beneficial effect on\u00a0markers of cartilage degradation and symptoms of spinal osteoarthritis. Those studies paved the way for the trial being reported on here, but there was no mention of that previous research.", "answer": 1}, {"article": "The researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nThey found 2,141 people with polyps, leaving 3,166 polyp-free controls. All patients were interviewed about diet, health habits and medical history.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least provided one line of context about past research in this field: \u201cAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\u201d", "answer": 1}, {"article": "Mr. Del Sontro is all too aware that the cause of his heart disease is a mystery, but he worries that if he fails to eat right and exercise he might make his illness even worse.\n\u201cOur main job is to find the gene,\u201d Dr. Biesecker said.\nStill, Mr. Del Sontro is preparing for the worst. He has life insurance and long-term care insurance.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research is certifiably novel, although other studies have looked for genetic determinants.", "answer": 1}, {"article": "Visit the American Heart Association for more on statins.\nPotluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty for this particular association of statins with decreased cancer risk. There have been a number of large meta-analyses and retrospective studies about statins and cancer risk reduction (all showing different findings), and this latest result should have been placed in context within the body of research.\nIt is implied (but not stated) that perhaps the use of 1 million patient records is the largest study searching for the correlation \u2013 but the story does not state it.", "answer": 0}, {"article": "More serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent). There were also two cases of cancer in people taking briakinumab and none in the methotrexate group. However, the researchers said these differences weren't statistically significant.\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\nOf the increased infections and cancers, Reich said, \"Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "On this point, WebMD\u2019s version of the story was better because it at least reminded readers that \u201ca similar drug, Stelara\u2026was approved by the FDA in 2009.\u201d", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that Erbitux was first used to treat colon cancer, but is now approved to treat head and neck cancer.", "answer": 1}, {"article": "\"If you think about it, the worst thing that you want is an immune system that's out of control,\" Loke says.\nWhen you first meet Moises Velasquez-Manoff, the first thing you notice is his hair \u2014 or the lack of it.\nBut this can help with something else. It can keep the immune system from getting out of control and attacking the body.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty by letting us know that studies go back a few years, so it\u2019s not a new concept.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains when the first paired organ donation took place, letting readers know this is not \u201cnew,\u201d per se, although a national policy allowing widespread paired organ donation would be new. ", "answer": 1}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\nAbout 40 percent of HCC cases are diagnosed at advanced stages, a point when HCC is particularly difficult to treat. This trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival. Results from the study, which included researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, were recently published online in The Lancet. The trial, funded by Bayer, included 152 sites in 21 countries.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that this is only the second pharmaceutical treatment for HCC proven to affect patient survival, and outlines what the study findings may mean for future research on how regorafenib may be used in treating earlier stages of HCC.", "answer": 1}, {"article": "The Food & Drug Administration recently approved the additional use of adalimumab (sold as Humira) for patients with noninfectious uveitis. Corticosteroids have traditionally been the only FDA-approved treatment for these diseases, although some doctors had prescribed adalimumab off-label.\n\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said. \u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty is somewhat nuanced, but explained well enough: Uveitis is a bag full of symptoms, and the damage involved can span across the entire eye. By measuring how it affected the most frequent symptoms, \u201cthe study\u2019s results broaden the applicability of treatment for patients\u201d and possibly help lead to longer-term solutions for uveitis.", "answer": 1}, {"article": "Public Relations Manager (School of Medicine and Dentistry) \n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed. However, the present results provide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\"\nThe main limitation of the study is that the reports are subjective. Future studies should assess respiratory symptoms objectively and on unselected samples of vapers. Despite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release is not the novelty of e-cigarettes but the novelty of the research. We give it a satisfactory for including this statement which puts the research in context:\n\u201cSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels. Human trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\u201d", "answer": 1}, {"article": "However, experts caution that it is possible to overdo it, and more exercise than two and a half hours a week can actually be unhelpful and even harmful. One study, published in 2014 in the journal Heart, suggests that in people with existing heart disease, the risk for cardiac arrest and stroke was the same for people who exercised more than an hour a day compared with those who didn\u2019t exercise at all. The coronary heart disease patients who stuck with the recommended 150 minutes a week had the lowest risk for heart attack and stroke.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise. You just need to do it.\nHowever, there are also some limitations to this study, the researchers say. More than 90 percent of the subjects were white. The information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym. Unfortunately, taking 20 minutes in locker room to put on your sneakers doesn\u2019t count as a workout.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish what\u2019s novel, unlike what we saw in our review of The Guardian\u2019s story.", "answer": 0}, {"article": "A neurosurgical procedure in which an implanted neurostimulator delivers electrical signals to specific areas of the brain to help regulate abnormal signals, DBS is currently only approved in the U.S. for the treatment of Parkinson's disease and essential tremor. However, its use is being researched for a number of conditions, including epilepsy, depression and bipolar disorder. Francisco Ponce, MD, Director of the Barrow Center for Neuromodulation, believes there are potential applications for Alzheimer's disease - the most common form of dementia - as well. Whereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method. While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population. The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release implies novelty by stating that the research \u201chelps pave the way\u201d for a new treatment option. Deep brain stimulation is used for other brain disorders, so it is obviously not a new device or new surgical approach, and the release makes this clear. However, as an approach to treat Alzheimer\u2019s disease it is novel.", "answer": 1}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research. \"The goal is to create cells that are missing or defective in people. It's very exciting.\"\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach described \u2013 while novel \u2013 is certainly not unique (viral vector for treatment of a chronic disease).\u00a0 Additional comments on the approach used by other reseachers would have added a needed balance.\n\u00a0", "answer": 0}, {"article": "Washington University School of Medicine\u2019s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children\u2019s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children\u2019s hospitals, the School of Medicine is linked to BJC HealthCare.\nHighlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean. There are few circumstances when a single study should change our practice. But based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk. Rather than prepping patients with iodine-alcohol \u2014 a common antiseptic combination in C-sections \u2014 the research indicates that chlorhexidine-alcohol is significantly more effective. The researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explained that other studies have examined skin-prep, but this one was the first to directly compare dual-element preps for C-sections. Here is an excerpt:\n\u201cPast trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone. These studies could not determine whether the worse performance of iodine alone was due to the chlorhexidine, the alcohol or the combination.\u201d", "answer": 1}, {"article": "About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.\nNew clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions. Notably, participants did not take any MS medications after receiving HDIT/HCT. Other studies have indicated that currently available MS drugs have lower success rates.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release explains the significance of the study in supporting initiation of a randomized trial. However, the results are not entirely \u201cnew,\u201d as the release states; they were previously reported at a medical conference in June 2016. Also, we found it interesting that the published study states its results are consistent with three similar trials, including this Canadian study, bolstering the validity of its finding. Those trials are not mentioned in the news release.\nThe idea of using bone marrow transplantation for medical illnesses is not new. During the 1990s bone marrow transplantation following high dose chemotherapy was touted as a cure for breast cancer. \u00a0A randomized clinical trial was begun in the late \u201990s but was discontinued when results from the initial studies were found to\u00a0have been fraudulently reported. (Described in a book called \u201cFalse Hope: Bone Marrow\u00a0Transplantation for Breast Cancer\u201d by Peter D. Jacobson and Richard A.\u00a0Rettig.)", "answer": 0}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day. \"With diet plus a supplement combined, women should be getting 1,000- to 1,500-milligrams a day,\" she said.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nDr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center, said that the study really doesn't provide enough information to make a definitive conclusion.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a great job explaining why these study findings are an important step in sorting out the role of calcium in heart health while showing that this study alone will not answer all the questions patients might have.\n", "answer": 1}, {"article": "LONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\nInvestor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses. The new study, which only involved 28 patients, is modest fillip.\nRinne\u2019s imaging study was funded by Elan and Wyeth, which is now part of Pfizer. (Editing by Jon Loades-Carter)\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The drug reported on, bapineuzamab, is currently the focus of a number of clinical trials, many of which are recruiting participants. \u00a0(www.clinicaltrials.gov). \u00a0The focus of this story was on a very tiny study which was more about methodology for assessing Alzheimer\u2019s disease. \u00a0So while the story made it seem like it was reporting on a study of a novel drug, it failed to mention the much larger studies of this drug that are currently in the works.", "answer": 0}, {"article": "SACRAMENTO, Calif. (Aug. 22, 2017) - A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer's. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system. Here are several highlights:\nIn the new article, the researchers report on a 16-patient clinical trial to demonstrate the feasibility of identifying beta-amyloid in the eye using autofluorescence imaging. They also provide detailed analyses and several new findings on Alzheimer's pathology in the retina, results of research with donated eyes and brains of 37 deceased patients, 23 with confirmed Alzheimer's disease and 14 controls.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the novelty of the findings in several areas, noting:\nThe article provides new insights into the disease\u2019s manifestations in the retina and information on the optical imaging system. Here are several highlights:", "answer": 1}, {"article": "The device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says. She wears her device while she sleeps.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019ll give the story a satisfactory score because it at least explained the following:\n\u201cthe trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.In 2005, the FDA approved a device that stimulates another nerve that leads to the brain \u2014 the vagus nerve. But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone.\u201d\n", "answer": 1}, {"article": "Swedish scientists found that weight-loss (or \"bariatric\") surgery before pregnancy lowers the chances of certain complications for mothers and babies but raises the odds for others. They recommended any pregnancy after weight-loss surgery be considered high-risk and receive stricter monitoring.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\n\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story quotes the study author about previous research in this area. \u201cThe positive effects of bariatric surgery on health outcomes \u2014 such as diabetes and cardiovascular disease \u2014 are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes.\u201d We\u2019ll call that statement barely good enough for a satisfactory rating. The NEJM paper refers to a number of studies and reviews of studies examining this issue. It would have been nice to describe how the current study confirms or differs from those studies and why.", "answer": 1}, {"article": "Glaucoma affects 60 million people in the world, with 1 in 10 suffering total sight loss in both eyes.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nThe examination uses equipment used during routine hospital eye examinations. Researchers hope that eventually it may be possible for opticians to do the tests, enabling even earlier detection of the disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to the tool under development as a \u201cpioneering diagnostic.\u201d A researcher is quoted saying, \u201cNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.\u201d\nWe\u2019ll give the release the benefit of the doubt that the test may potentially be novel for glaucoma but not for any neurological disease for which it hasn\u2019t even been tested.", "answer": 1}, {"article": "All of the participants kept hot flash diaries. At the end of the three-month period (and for up to six months thereafter) daily hot flash experiences were assessed for changing severity and frequency.\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the weakest spot for the story. We found\u00a0three other papers that evaluated acupuncture as a means of addressing hot flashes for cancer patients: this one from 2007, one from 2009, and another from 2009. The findings from the studies are not all in agreement (with each other, or with the study being discussed in this story).\nWhat does it tell us that we didn\u2019t already know? Does it build on previous work? Looking at all of the work on this subject, what do we know about this form of treatment? Those are good questions\u2013important questions\u2013and this story doesn\u2019t address them.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news hook here is the FDA approval of this drug combination. We\u2019ve already given the story credit for this above under \u201cAvailability.\u201d And we\u2019d note that just because the FDA approves something, doesn\u2019t mean that it\u2019s novel. There are plenty of \u201cme-too\u201d drugs out there, and this story doesn\u2019t make any attempt to clarify how this new drug combination works differently or better than existing drugs.", "answer": 0}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\nThe traditional means for getting at misfiring cells relies on pre-intervention X-rays for a much less precise snapshot form of visual guidance.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The word \"new\" was used five times in the short story.\u00a0 Yet the real novelty of this approach is only scantily and insufficiently described \u2013 especially if the implication is that this has relevance for 2.2 million Americans. ", "answer": 0}, {"article": "Psoriasis is a condition that affects 7.5 million Americans, according to the National Psoriasis Foundation. It is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime. Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin. Psoriatic arthritis is similar in presentation -- but also can lead to joint pain.\n\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center. \"These findings can be used to identify people who may benefit most from this type of intervention.\"\nThe researchers say excess weight loss may reduce the body-wide inflammation and pain triggered by extreme excesses of fat tissue. They plan to present their findings on Sunday Nov. 8, 2015 at the 2015 ACR/ARHP Annual Meeting in San Francisco.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "One could easily come away from this release thinking that these researchers are the first to report psoriasis symptom reduction in those undergoing bariatric surgery (with resultant weight loss). However, such findings have been reported before, and the release does not acknowledge this.", "answer": 0}, {"article": "For its part, tamoxifen is also associated with serious side effects, which can include cataracts and uterine cancer as well as life-threatening blood clots and stroke.\nThe paper, issued by the American Society of Clinical Oncologists (ASCO) and published July 12 in the Journal of Clinical Oncology essentially brings guidelines in alignment with today's practice.\nThose studies and presentations, added Denlinger, \"have uniformly demonstrated the superiority of aromatase inhibitors over tamoxifen or a switching strategy or an extended strategy.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that tamoxifen is not new and that aromatase inhibitors \u201care a more recent entry into the field.\u201d The story also states that aromatase inhibitors have been a standard part of care before the guidelines\u00a0were released.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the procedure has been in use for decades. What could have used more exploration\u2013from independent sources\u2013is whether it\u2019s overused.", "answer": 1}, {"article": "Learn more about both types of diabetes and treatments from the National Institute of Diabetes and Digestive and Kidney Diseases.\nLeone-Bay said that cancer studies have been conducted on Afrezza in rats. The rats got a much higher inhalation dose than humans would take, and the researchers didn't find an increase in lung cancer. She said these types of studies weren't done on Exubera.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes. Because it's fast-acting, it can't provide the long action of insulin known as basal insulin. It will only replace meal-time insulin.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article doesn\u2019t explain how the inhaler technology differs from that used in Exubera, only that Afrezza is a dry powder dissolved in the lungs, absorbed into the bloodstream. \nAlso, from what we can see, the overall therapeutic role of Afrezza is no different than that of Exubera. People who need to take insulin to treat their diabetes would need injections of long-acting (basal) insulin and then puffs of mealtime (prandial) insulin. From what we are told in this story, the true novelty of Afrezza over Exubera would be a) its shorter mechanism of action and b) the fact that Exubera has ceased to be. They haven\u2019t demonstrated that Afrezza has a different safety profile in humans from that of Exubera. (Other sources we found quote Dr. Leone-Bay noting that the Afrezza inhaler has unique properties.) The claim of superior glucose control over injectable insulin is unsubstantiated in the story, yet it\u2019s critical information.", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nIn terms of calories, flavor and appearance, the placebo and treatment drink were identical.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "References to past research on seaweed supplements were made.", "answer": 1}, {"article": "Parkinson\u2019s disease is characterized by reduced levels in the brain of the hormone dopamine, a neurotransmitter that allows different regions of the brain to communicate with one another. Symptoms of advanced Parkinson\u2019s disease include an impaired sense of balance, as well as tremors, poor mobility, slowness and stiffness.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home. If those trials prove successful, the developers hope the device could be available to the public within five years.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the TENS technology has found use in other areas of medicine.", "answer": 1}, {"article": "No measurable effect from ginkgo is seen on cognition, Schneider said. \"Regardless of whether people say 'I take it and I feel better,' you just don't see an effect,\" he said.\nThe report, published in the Dec. 23-30 issue of the Journal of the American Medical Association, supports the findings of earlier, smaller studies.\nThe American Botanical council took issue with the findings, however.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these products is not in question. ", "answer": 2}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is story makes it clear this is a novel drug in the\u00a0early phase of testing. ", "answer": 1}, {"article": "Mpourmpakis and Taylor applied density functional theory (DFT) - a highly accurate computational method used to study the structure and properties of materials - to address how HCA and CA bind to calcium and to calcium oxalate crystals. They discovered HCA formed a stronger bond with crystal surfaces, inducing a strain that is seemingly relieved by the release of calcium and oxalate, leading to crystal dissolution.\nThe project grew out of preliminary work done by collaborator John Asplin, a nephrologist at Litholink Corporation, who suggested HCA as a possible treatment. HCA is chemically similar to CA and is also available as a dietary supplement.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There do not appear to be any other studies available on www.PubMed.gov that look at hydroxycitrate as a potential kidney stone treatment.", "answer": 1}, {"article": "-A single PSA blood test at ages 44 to 50 might help predict a man's risk of developing advanced prostate cancer or dying of it up to 30 years later. The PSA test is notoriously unreliable, but using it this way separates men who need a close watch from those who are so low-risk that they can skip testing for five years or more.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\nHowever, if an HPV test was positive, a Pap test helped confirm or rule out the need for follow-up.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Where novelty was at issue, the story establishes novelty, saying, for example, \u201cThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\u201d", "answer": 1}, {"article": "Yet stroke patients admitted on the weekends were no more likely to die than stroke patients admitted during the week: 1,420 patients admitted on the weekend died versus 3,993 patients admitted on a weekday, which worked out to roughly the same rate of death.\nBut Kazley said that the additional deaths among patients who received tPA is likely because doctors are more likely to give the drug to those with severe strokes, who have a higher risk of death in any case.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story does not suggest that tPA is a novel treatment for stroke.", "answer": 1}, {"article": "A study in 2008 suggested that removing clots during an angioplasty might save lives, he said. \"Guidelines changed based on this study,\" Jolly noted. Another trial in 2013, however, suggested that removing clots was not beneficial, he added.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that there was prior research on this topic showing benefit from clot removal.", "answer": 1}, {"article": "The regimen included exercising four to five times a week, generally in 30-minute sessions, plus warmup and cool-down:\nThe new study appears in Circulation, a journal of the American Heart Association. Collaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia. Funding came from the National Institutes of Health and the American Heart Association.\nTo start the study, researchers recruited 53 participants, ages 45 to 64. Many came from the Dallas Heart Study, which includes 6,000 Dallas residents and is the only single-center heart study of its size and multiethnic composition. The Dallas Heart Study is designed to improve the diagnosis, prevention, and treatment of heart disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions early research by cardiologists from the same institution documenting stiff left ventricles in middle-aged people who don\u2019t exercise. It\u2019s mentioned that this study is unique in asking the question: can exercise restore heart elasticity in previously sedentary, middle-aged people?\nWe\u2019ll rate this satisfactory. But really, this is just one of innumerable studies that show exercise is beneficial. It might be measuring the benefit in a novel way but, in the end, it is just suggesting that exercise is good.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Physicians have treated Parkinson\u2019s patients with the drugs pergolide and cabergoline for a long time. The news article accurately represents their controversial history, though it neglects to note that other medicines in this drug class are avaliable that do not appear to cause heart valve disease.", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the RapidArc may be new to the market, the story provided no insight as to how the radiation treatment from this device compares to others on the market. \u00a0Is it delivering something that is truly unique or are there other systems out there that can similarly focus the radiation beam used in treatment? (In fact \u2013 going to the company website, it appears that RapidArc is just a modification of existing intensity-modulated radiation therapy technology. The story says RapidArc is used in conjunction with IMRT and image-guided radiation therapy.\u00a0 But what does that mean?)", "answer": 0}, {"article": "\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence. CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nThe Phase 2 study was a three-center, randomized, double-blind, inpatient study to evaluate the degree of subjective opioid blocking efficacy of CAM2038 q1w in non-treatment-seeking participants with moderate-to-severe opioid use disorder. After screening, participants were randomized to different CAM2038 q1w once-weekly injections for two weeks. During this period, four challenge sessions were conducted with a randomized hydromorphone dose to determine subjective 'liking' score based on a visual analogue scale. Additional information on the design of the trial can be found at www.clinicaltrials.gov .\nBraeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead candidate, Probuphine\u00ae, a six-month buprenorphine implant for treatment of opioid addiction. The Agency set May 27, 2016 as the target date for action.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests the product under development is \u201cnovel\u201d and that it \u201chas the potential to alter the current treatment paradigm for opioid dependence.\u201d We aren\u2019t really told what is novel about the formula, though. A weekly or monthly administered opiate antagonist would be a new addition to the treatment options but it is not really novel.", "answer": 0}, {"article": "Alzheimer's Redefined, But Changes Mean Little For Patients\nThe second new phase, preclinical Alzheimer's, is much squishier. There's no list of symptoms that a doctor can whip out to say you've got it. Rather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests. If that happens, it might someday lead to ways to prevent Alzheimer's. But for now this category is useful only to researchers.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story summarizes key components of the new definitions of the stages of Alzheimer\u2019s disease that are different from those used in the 1984 guidelines. It points out that lab tests and brain scans have not been shown to be accurate and reliable in ways that would make them useful in clinical settings, as well as some of the questions that remain about how the results would be used.  A more complete description of which biomarkers are being studied would have been a good addition.", "answer": 1}, {"article": "For measuring sleep quality, participants wore an armband that measures skin temperature, heat flux, bed temperature and skin moisture levels. They also wore a sensor that tracked their movements at night, including indications of restlessness.\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\n\u201cSleep quality is affected by many factors, such as health and emotional states, bedding conditions and different environmental conditions, including noise levels and temperature,\u201d said Dr. Nuno Canha of the University of Lisbon in Portugal. Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns. He is also part of LIFE Index-Air, a European research group that focuses on human exposure to pollutants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish what makes this research novel. It\u2019s fairly well-known that indoor air quality can be poor, and that ventilation can help circulate the air.", "answer": 0}, {"article": "The main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes. The MedDiet is also low in dairy, has minimal red meat, and uses olive oil as its major source of fat.\n\"The most surprising result was that the positive effects were found in countries around the whole world. So regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers;\" he said.\nLeading author Roy Hardman from the Centre for Human Psychopharmacology Swinburne University of Technology Melbourne Australia and his colleagues evaluated all the available papers between 2000-2015 that investigated if and how a MedDiet may impact cognitive processes over time. In total, 18 out of the 135 articles met their strict inclusion criteria.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Studies of this diet are numerous. Although this meta-analysis may be unique in its analytical characteristics, the text makes no claim for novelty.\nThe release includes quotes which make the study sound like new information, when it really isn\u2019t. For example:\n\u201cThe most surprising result was that the positive effects were found in countries around the whole world. So regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers.\u201d", "answer": 0}, {"article": "These real-life cyborgs hack their bodies with chips, magnets and other tech\nShe is hardly alone in her suffering. According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain. It can interfere with work and home life and leave patients debilitated, disabled and depressed. So it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nShe also describes her path to spinal stimulation, how the device works with the body to short-circuit pain, and the many roadblocks to relief that patients face.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Spinal cord stimulation appears to have been around for years, though the marketing of these devices appears to be on the upswing. One concern: The piece refers to her getting a \u201cnext generation stimulator. This implies that there is a prior generation one, and we\u2019re not sure what the difference is.", "answer": 1}, {"article": "To request a copy of the study or to request an interview with a study author, please contact Jessica Frost at 202-527-7342.\nWASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets. The meta-analysis appears as an online advance in Nutrition Reviews.\n\"The immediate health benefits of a plant-based diet, like weight loss, lower blood pressure, and improved cholesterol, are well documented in controlled studies,\" says study author Susan Levin, M.S., R.D., C.S.S.D. \"Our goal with studying plasma lipids throughout the lifespan is to capture the net risk reduction of using a vegetarian diet to control lipid levels. We hope to empower patients with new research about the long-term cardiovascular health benefits of a vegetarian diet, which include a reduced risk of a heart attack, stroke, and premature death.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Is it novel to show that vegetarian diets are associated with lower cholesterol? Other studies have examined the relationship between vegetarian diets and plasma lipid levels, and comparing them with omnivorous diets, found there was no difference in high density lipoprotein cholesterol (HDL-c).\nWe wondered if there was some other aspect of the study that made it novel. The release notes that the study goal was to examine the association between a vegetarian diet and plasma lipid levels \u201cthroughout the lifespan.\u201d According to the published study, this was the first meta-analysis to do so on a \u201clong-term\u201d basis. However, to be included in the analysis, clinical trials and observational studies only had to be 4 weeks of duration \u2014 hardly \u201clong-term.\u201d\n\u00a0", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nBut getting the treatment to the right target in the body has presented a challenge.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach is discussed appropriately. ", "answer": 1}, {"article": "In 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute. And an estimated 40,560 will die from the disease. It is the most deadly cancer with just 7.2 percent surviving five years.\nWhile quite promising, the new findings will need to be verified and validated by other studies, experts told NBC News. And even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nEven more promising are the findings from the seven patients with early pancreatic cancer that were detectable through their protein levels. Further, levels dropped when patients had surgery to remove their tumors, so the marker could also be used to follow the progression of the disease, Kalluri said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The findings are presented as novel, but novelty is not established. There\u2019s no discussion of whether there has been other research into tests for pancreatic cancer and how the new test builds upon those previous efforts. We can infer that this is new, but the context is not established.", "answer": 0}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet. The vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD). Both diets were restricted by 500 kilocalories per day compared to an isocaloric intake for each individual.\nDieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\nThey found that both diets caused a similar reduction in subcutaneous fat. However, subfascial fat was only reduced in response to the vegetarian diet, and intramuscular fat was more greatly reduced by the vegetarian diet.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes what the study set out to do \u2014 measure changes in weight and in subfascial and intramuscular fat and how these change can impact metabolism. But the study isn\u2019t novel. Numerous studies have been conducted on the effects vegetarian diets have on different types of body fat as well as weight and metabolism.", "answer": 0}, {"article": "Thrombectomy involves a catheter placed in the femoral artery and snaked up the aorta and into the cerebral arteries where the clot that is blocking the artery, and causing the neurological symptoms, is retrieved.\nThe researchers planned to enroll a maximum of 500 patients over the course of the study period. However, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nThe DAWN trial included trial locations in the United States, Spain, France, Australia and Canada. The trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release might have noted that previous research had suggested that some extension of the six-hour timetable for optimal clot removal was possible, even for medical therapy. But overall, the release makes clear why and how this trial was novel.", "answer": 1}, {"article": "The trend reflects an evolving understanding of breast cancer. In decades past, there was a belief that surgery could \u201cget it all\u201d \u2014 eradicate the cancer before it could spread to organs and bones. But research has found that breast cancer can begin to spread early, even when are small, leaving microscopic traces of the disease after surgery.\nThe results mean that women like those in the study will still have to have at least one removed, to look for cancer and decide whether they will need more treatment. But taking out just one or a few nodes should be enough.\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that a change in treatment protocol away from removing all the lymph nodes under the arms of women with breast cancer would be novel.\u00a0There is some nuance, here, though that could be missed by a casual reader. Women who have one to two positive lymph nodes would avoid having additional lymph node surgery. The overall tone of the story may make it appear to some readers that women get to avoid lymph node surgery altogether, but they don\u2019t.", "answer": 1}, {"article": "This is one of very few studies that looks at olive oil intake and risk for neurologic diseases, including stroke, Nikolaos Scarmeas, MD, of Columbia University in New York City, says in an email. \u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says. \u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says. \u201cNow, we see it may reduce stroke risk in people older than 65.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the study\u2019s focus was clear in the story.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes how the new tests wed radioactive tracing materials with an amino acid (in the case\u00a0of the prostate cancer) and other molecules, and sufficiently explains how the new tests differ from current nuclear images.", "answer": 1}, {"article": "The Johns Hopkins group reported that psilocybin decreased clinician- and patient-rated depressed mood, anxiety and death anxiety, and increased quality of life, life meaning and optimism. Six months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range. Eighty-three percent reported increases in well-being or life satisfaction. Some 67 percent of participants reported the experience as one of the top five meaningful experiences in their lives, and about 70 percent reported the experience as one of the top five spiritually significant lifetime events.\nAnticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K. Medicines and Healthcare Products Regulatory Authority. In general, the commentaries were supportive of the research and of using these drugs in a clinical setting as tools for psychiatry.\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release places the work in the context of previous research from Johns Hopkins, which is enough \u2014 barely \u2014 to earn it a satisfactory rating here. What we would really like to see is how this work compares to previous research done specifically on the use of psilocybin to treat anxiety in cancer patients \u2014 such as this 2007 study, this one from 2011, or this one from 2013. We don\u2019t necessarily expect an exhaustive comparison, but there needs to be at least some recognition that other work has been done in this field over the past 10 years.", "answer": 1}, {"article": "For more on the opioid epidemic, read Vox\u2019s in-depth explainer, the abridged explainer, or the maps and charts explainer.\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs. If someone genuinely suffers from pain and anxiety, doctors and patients will need to work out which condition is more important to treat and which one can be treated with alternatives \u2014 to avoid a potentially deadly overdose. (Hopefully while keeping in mind that there\u2019s no good scientific evidence that opioids can treat chronic pain, so opioids aren\u2019t the right treatment for chronic pain in the first place.)\nThe drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety. These drugs were involved in nearly 9,000 overdose deaths in 2015, according to federal data. But there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says researchers \u201cjust uncovered\u201d the danger of tandem opiod/benzodiazepine use and quotes a researcher saying the study \u201creveals an underappreciated policy lever for reducing drug overdoses: Making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\u201d\nIn fact, this has been the radar of the medical community for awhile. A 2015 study found veterans using opioids had a higher risk of death from drug overdose if they also used benzodiazepines. And last year two government agencies took action: The U.S. Centers for Disease Control and Prevention amended guidelines to discourage clinicians from prescribing both types of drugs simultaneously, while the FDA advised of the dangers of mixing the drugs and strengthened warning labels and patient medication guides for nearly 400 products.\nInstead, the challenge has been figuring out how to get patients off of this drug combination and recent\u00a0research/care delivery redesign efforts are tackling this issue (but this article doesn\u2019t not get into this at all, nor is this what the research study is about).", "answer": 0}, {"article": "Especially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\nInexperienced doctors might also take advantage of the robot for surgery if they don\u2019t think they have the skills to do the surgery with only a small cut, Dr. Nezhat said. In this case, the robot could turn what would have to be an open surgery into a simpler one.\nThe robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty here is that the humans beat the robots. It would have been nice to see at least a sentence about whether other studies had shown similar results with other types of surgeries. Was this the first man-vs.-machine study of this kind?", "answer": 0}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older. It is much rarer for men younger than 40 years old to develop prostate cancer.\nGet more of Dr. Samadi's take on this study and its effect on the field of Prostate Cancer on Fox News Sunday Housecall.\nVisit ProstateCancer911.com and call 212.365.5000 to set up your consultation.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The findings reported in the study seem to be newsworthy, and we\u2019ll give credit\u00a0for indicating that \u201cnew research has revealed\u201d and \u201cthis discovery\u201d as\u00a0establishing novelty. There\u2019s also a nod to previous research about prostate cancer genetics.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.\n\u201cAlthough we found an association between women who experience less pain during labor and lower risk for postpartum depression, we do not know if effective pain control with epidural analgesia will assure avoidance of the condition,\u201d said Dr. Lim. \u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\u201cLabor pain matters more than just for the birth experience. It may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study. \u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While technically a novel result, it\u2019s a minor one. We found a 2014 study in Anesthesia & Analgesia that explored the same question, though in a Chinese population and with greater rigor. That study compared women who chose epidurals to those who chose a \u201cnatural\u201d birth without epidurals. Interestingly, we found a 2015 commentary that responds to this 2014 study \u2014 and it was authored by Lim (the lead author of the new study), who rightfully states that, if epidurals do decrease the risk for postpartum depression, then \u201cit could have tremendous ramifications on the long-term mental well-being of half of the world\u2019s population who are of child-bearing age.\u201d Lim\u2019s letter also called for more research with larger sample sizes to try and replicate the results. But roughly one year later, Lim\u2019s abstract explores the question with no overt controls and a similar sample size.", "answer": 0}, {"article": "ColonaryConcepts, LLC is headquartered in Newton, MA, and is committed to developing patient-centric innovations that improve gastrointestinal health. The company currently has two product candidates in clinical development: ECP, which is expected to enter Phase 3 clinical trials in early 2017, and the \"C-bar\", a novel product candidate for chronic constipation, which is currently being studied in a Phase 1b clinical trial. ColonaryConcepts' physician-led product development team includes Board-certified gastroenterologists, food scientists, pharmaceutical development experts, culinary research chefs, and product design strategists. For more information about ColonaryConcepts, LLC, please visit http://www.\n\"Approximately 40% of those who ought to have a colonoscopy avoid the procedure, and the top reason cited for their avoidance is the prep,\" said Dr. Rex. \"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations. Moreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\nResults from the randomized, single-blind study will be presented today at the American College of Gastroenterology 2016 Annual Scientific Meeting, being held in Las Vegas, NV, by principal investigator, Douglas K. Rex, M.D., Distinguished Professor of Medicine, Indiana University School of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release uses the term \u201cnovel\u201d to describe this new prep formulation. \u00a0Although a variety of preps are now available, this study\u2019s novelty appears to be its high level of patient satisfaction.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the true novelty of the approach?", "explanation": "What appears to be \u201cnew\u201d is the explosion of combing salons and newer prescription shampoos, as well as the review article published last week that evaluates them.", "answer": 1}, {"article": "Of course, there are other benefits to more frequent and more intense bouts of exercise. Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nThat exercise doesn\u2019t have to be intense, either, they say. People seemed to have mental health benefits from physical activity regardless of whether they reported working out to the point of exhaustion or barely breaking a sweat.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Exercise for mental health is not a new concept. What makes this study novel is that it\u2019s looking at exercise\u2019s potential to prevent depression, and if that impact would be useful enough for a public health level initiative. As the study explains:\n\u201cWhile many agencies are keen to promote the potential mental health benefits of exercise, at present the literature is unable to provide the most basic information needed for effective, targeted, evidence-based public health campaigns concerning depression and anxiety.\u201d\nThe story didn\u2019t explain this.", "answer": 0}, {"article": "Transcranial magnetic stimulation, once considered an experimental treatment for depression, is gaining acceptance since it came on the market four years ago. Beginning Saturday, Medicare will cover the treatments when other therapies have failed. This week, specialty insurance administrator Magellan Behavioral Health Inc. issued medical necessity guidelines for TMS treatment and will provide coverage effective Jan. 1.\nDr. Michelle Cochran, purchased her TMS system about 18 months ago. The devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nThen she agreed to a transcranial magnetic stimulation. The new treatment pushes powerful magnetic currents into the front of the brain, the part that controls emotions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that the device approved in 2008 is novel as is the underlying approach to treating depression", "answer": 1}, {"article": "\"None,\" he said.\nUnlike methadone, Suboxone can be prescribed by any doctor, even a family physician, so treatment for addicts can now be convenient and discreet.\nPatients in the trial are given counseling as well as a new kind of anti-addiction drug called Suboxone. It's an orange pill that's dissolved under the tongue.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment in places implies the drug is new and novel (by referring to the current clinical trial, by using the word \"new\" to describe it, and by emphasizing its hope for revolutionalizing treatment). But it also states that it is currently available. This leaves the viewer uncertain about what\u2019s \"new\" here.\nSo what is new? Buprenorphine has been an approved parenteral analgesic for decades. The drug was approved in 2002 as an alternative to methadone\u2013a drug to be taken as a more benign replacement for the more addicting drug being abused, such as heroin. It enables withdrawal from the addicitive drug, which may be followed by other addiction treatments or maintenance therapy.\u00a0 \nThe current trial involves only patients who are addicted to painkiller medications like OxyContin. The study is designed to determine whether those taking Suboxone and getting supportive counseling can taper off Suboxone fairly quickly and become entirely drug-free.\u00a0\u00a0 ", "answer": 0}, {"article": "2) Savoring that positive event and logging it in a journal or telling someone about it \nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThe positive emotion intervention also improved mental health. At baseline, about 17 percent of the control group and intervention group reported being on antidepressants. Fifteen month later, the intervention group was still at 17 percent but the control group's antidepressant use rose to 35 percent.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release contains this claim of novelty:\n\u201cThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\u201d\nWe believe others in medicine have probably used \u201cpositive\u201d intervention before, but they may have called it support or emotional coaching or many other phrases. Cognitive-behavioral therapy, massage, and other means to improve a person\u2019s coping skills could be considered \u201cpositive emotion intervention.\u201d", "answer": 0}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe abstract was one of thousands of studies released on Thursday ahead of presentation at the American Society of Clinical Oncology (ASCO) next month in Chicago.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that what is new about the highlighted trial is that it looks at using this experimental drug in a subset of patients, those with melanoma that has spread to the brain. However, readers might be misled by the apparently inaccurate description of the second trial in the story, as noted above.", "answer": 1}, {"article": "\"A risk stratification tool is critical in helping physicians make appropriate screening recommendations for patients,\" Garbus said. \"While high-risk patients may ultimately require a screening colonoscopy, many average- and low-risk patients could undergo less invasive screening procedures. This can improve patient compliance with screening, as well as address escalating health care cost issues.\n\"Five percent of the U.S. population will be diagnosed with colon cancer within their lifetimes,\" said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City. He was not involved in the new research.\nTUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low. Now, researchers say a special scoring system might point to those people at highest risk for colon cancer, who may need the test the most.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound as if this is a first-of-its-kind tool. However, risk calculation tools for colon cancer have been in circulation for many years.", "answer": 0}, {"article": "Previous U.S. studies found that people with autism who received the hormone intravenously were less likely to engage in repetitive behavior that is another hallmark of autism and were more likely to be able to identify emotions in voices. Another study being published in the journal Biological Psychiatry found that 16 autistic males in Australia ages 12 to 19 who received the hormone through a nasal spray were better able to recognize other people's facial expressions.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there have been previous studies of oxytocin in autism.", "answer": 1}, {"article": "But conventional germicidal lamps aren\u2019t safe for humans to be around. With prolonged exposure, they can cause skin cancer and cataracts in the eyes. \u201cSo up until now, they\u2019re only really practical when people aren\u2019t around,\u201d say Brenner. \u201cYou can sterilize a hospital room, but not when anyone\u2019s inside.\u201d\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza. In their new study, aerosolized particles of the H1N1 seasonal flu virus were released into a test chamber and exposed to very low doses of far-UVC light. The light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria not exposed to light remained active.\n\u201cWe wanted to get all the benefits of UV light in terms of killing microbes, but none of the health hazards,\u201d says Brenner. Earlier studies, on animals and humans, have shown that exposure to far-UVC light does indeed appear to be safe. \u201cWe haven\u2019t seen any biological damage to skin cells or eye cells, whereas with conventional UV light we\u2019ve always seen lots of biological damage,\u201d he says. Previous research has also shown that far-UVC light can kill MRSA bacteria, a common cause of infections after surgery.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is made clear the authors have studied this type of light in killing methicillin-resistant staph. aureus (MRSA), but it\u2019s not clear if the current study is the first to apply far-UVC light to an influenza virus (in the published study the authors claim this is the first time far-UVC light has been assessed for inactivating aerosolized viruses).", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon. However, few foods naturally contain the vitamin. Your body also makes vitamin D after the skin absorbs some of the sun\u2019s rays. Sunlight is one of the most important sources of vitamin D.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy. It revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult. Among the nurses studied, 199 developed MS over the 16-year study period.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story indicates that other studies have found a link between vitamin D and MS.\u00a0 ", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Although the story could have\u00a0provided more background on the history of\u00a0anti-addiction vaccines (a\u00a0heroin vaccine was explored in the 1970s), the treatments being explored now are different from\u00a0anything currently available. So we don\u2019t think this story overstates the\u00a0novelty\u00a0of the research.", "answer": 1}, {"article": "A lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus. A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\n\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do. A glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow. From there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen. You must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n\nThe fact that recognizing and acknowledging a familiar person is such...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story provided an engaging look at the potential benefit for\u00a0deep brain stimulation to improve the condition of people in a minimally conscious state.", "answer": 1}, {"article": "A video in which Professor Probert explains how the machine works can be found here\nThe research team is now looking to fund a full clinical trial.\nProfessor Chris Probert from the University of Liverpool's Institute of Translational Medicine began work on this project with UWE Bristol when he was working in Bristol as a gastroenterologist with clinical and research interest in inflammatory bowel disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device is similar to many other technologies in development that are said to \u201csniff\u201d cancer based on specific odor signatures. But the release makes it sound as though this device is unique.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Pap smears rely on using a microscope to hunt for cancer cells, whereas the newer methods described use genetic testing. The story also notes how ultrasound and genetic blood tests for uterine cancers typically are used only when symptoms arise \u2014 an advanced stage of the cancers \u2014 since the those tests \u201cfail to detect many cancers, and also send up a lot of false alarms.\u201d The article places extra emphasis on so-called \u201cliquid biopsies,\u201d saying thy \u201chold the promise of revolutionizing cancer screening\u201d due to a lack of early screenings for these cancers. (That remains to be seen.)", "answer": 1}, {"article": "\"We have to give women some type of option,\u2019\u2019 said Beverly Whipple, a professor emeritus at Rutgers University and an expert on women\u2019s sexual health. \"I\u2019m hoping this will help the women who need it.\u2019\u2019\nWomen who took the medicine, known as flibanserin, reported 22 percent more \"satisfying sexual events\" than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.\nFlibanserin could be the first success after a series of failures from drugmakers including Pfizer and Procter & Gamble. Pfizer, the New York-based maker of Viagra, abandoned efforts to adapt its pill for women in 2004 and closed sex-health research at the end of last year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story is accurate in stating that\u00a0if approved, flibanserin would be the first drug of its kind for pre-menopausal women.\u00a0 It does acknowledge that\u00a0other efforts to produce a similar drug have been unsuccessful. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the new recommendations represent a departure from existing guidelines.", "answer": 1}, {"article": "American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe. As Ben-Gurion University of the Negev looks ahead to turning 50 in 2020, AABGU imagines a future that goes beyond the walls of academia. It is a future where Ben-Gurion U. invents a new world and inspires a vision for a stronger Israel and its next generation of leaders. Together with supporters, AABGU will help the University foster excellence in teaching, research and outreach to the communities of the Negev for the next 50 years and beyond. Visit vision.aabgu.org to learn more.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri. \"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not make clear that urine and breath tests have existed and been used for breast cancer, but the novel part of this study is the statistical analysis and modeling.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story establish the true novelty of the approach?", "explanation": "In the story Yale cardiologist Harlan Krumholz \u201csaid it represents one of the first times a professional medical society has looked at the appropriateness of its care in such a comprehensive fashion. \u201cIt needs to be a wake-up call for the rest of medicine to say this is what we need,\u201d he said.", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections. The lower their neutrophil count, the more vulnerable patients are to infectious diseases. In such cases the drug is temporarily discontinued and reintroduced at a lower dose. Other side effects included fatigue (33 percent), nausea (30 percent), diarrhea (18 percent), constipation (12 percent), and rash (12 percent).\nThe study was funded by Pfizer Inc and the National Institutes of Health (5P30 CA16520-25).\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn. These tools can help to individualize patient therapy going forward.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The drug is the first of a new class of drugs and that\u2019s noted in the release. ", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cThe pomegranate people are spending millions to prove what I could have told them in the first place,\u201d she added. \u201cPomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d\n\u201cPomegranate juice was shown in the last three years to contain the highest levels of polyphenols among a variety of products,\u201d Kristal said. \u201cMuch higher than red wine, for instance.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good job on this, citing research over at the last 3 years, but also concluding with this quote from Marion Nestle:\n\u201cThis study does not demonstrate anything special about pomegranate juice.The effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect. \u2026The pomegranate people are spending millions to prove what I could have told them in the first place. Pomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity. Does this make pomegranates better than any other fruit? Investigators have yet to show this.\u201d", "answer": 1}, {"article": "As a result, federal health officials have recommended that women bothered by menopausal symptoms such as unpredictable sweats, sleep disturbances and vaginal dryness take the lowest dose of estrogen for the shortest possible time. Hot flashes, one of the most common symptoms of menopause, affect an estimated 75 percent of women, most of them in their forties and fifties.\n\"Hot flashes are one of the most placebo-responsive conditions,\" she said. Some herbs and supplements seem to work, she added, but improvement has proven to be temporary. ?\nThe search for a benign, effective alternative treatment for hot flashes -- which has included the use of soy products, Chinese herbs and hypnosis -- has hit another roadblock.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Article notes that acupuncture has been used for more than 2,000 years.", "answer": 1}, {"article": "But in the decades since, numerous studies have shown, persuasively, that these overuse injuries do not involve inflammation. When animal or human tissues from these types of injuries are examined, they do not contain the usual biochemical markers of inflammation. Instead, the injury seems to be degenerative. The fibers within the tendons fray. Today the injuries usually are referred to as tendinopathies, or diseased tendons.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids). It had such a magical, immediate effect against pain. Today cortisone shots remain a standard, much-requested treatment for tennis elbow and other tendon problems.\nWhy then does a cortisone shot, an anti-inflammatory, work in the short term in noninflammatory injuries, providing undeniable if ephemeral pain relief? The injections seem to have \u201can effect on the neural receptors\u201d involved in creating the pain in the sore tendon, Dr. Khan said. \u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain. Instead, they actually \u201cimpede the structural healing.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe article specified that steroid injections have been employed for roughly half a century.\n", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A bit of historical information in the story makes it clear that online therapeutic agents have been around\u2014in various stages of development\u2014for more than a decade.", "answer": 1}, {"article": "Even when the test picks up a real cancer, doctors are uncertain what, if anything, men should do about it. Many men simply are monitored closely to see if the tumor shows signs of growing or spreading. Others undergo surgery, radiation and hormone treatments, which often leave them incontinent, impotent and experiencing other complications.\nOthers were highly critical, noting that prostate cancer death rates have plummeted in many countries after they instituted widespread PSA screening.\nSeveral other experts said that the new recommendations strike a careful balance, and that they hope they might discourage large-scale screenings where the risks and benefits are not carefully laid out.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was reporting on the release of new guidelines from the US Preventive Services task force, and highlighted that these recommendations differ from the previous version in that they specify that the benefit of routine screening of men older than 75 years of age for prostate cancer is little to none while at the same time, the harms are moderate-to-substantial.", "answer": 1}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier. Hormone treatment gives the body a smoother landing from menopause to post-menopause.\nNow doctors are once again saying they shouldn\u2019t have to.\nThe sheer number of choices today and the need for a thorough initial health assessment make the decision on hormone therapy highly dependent on close communication between a woman and her doctor, experts say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about the approaches described in the story.", "answer": 2}, {"article": "Ongoing updates are expected in journals and meetings later in 2017.\nTucatinib is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 \"tyrosine kinase\" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. The fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease. HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated had progressed despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least \"stable disease\" at 24 or more weeks after the start of treatment. These data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the \"pivotal\" trial that will determine approval.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that tucatinib is unusual because it is taken in pill form, meaning women do not need to visit infusion centers for treatment. It also suggests that tucatinib is unusual because of its small molecular size, enabling the drug to pass the blood-brain barrier. However, no information is provided about how many, or how few, other cancer drugs can be taken in pill form or whether any other anti-cancer drugs currently in use or in testing also can pass through the blood-brain barrier.", "answer": 1}, {"article": "And women who had ovaries removed reduced their risk of ovarian cancer by as much as 80 percent.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nOne of the women who decided to take that chance is 61-year-old Toby of New Jersey. (Because she's worried about her health coverage, she doesn't want her last name used.)\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story points out that this latest study is building on earlier work.", "answer": 1}, {"article": "Anal cancer that has spread to lymph nodes is linked to a worse prognosis and lower chance of survival.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients. By identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nJill adds: \"Anal cancer is on the increase and those of us who have been through what at times was gruelling radiotherapy regimen, welcome this study and the impact it will have on the treatment plans of patients in the future.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release is fairly clear that the meta-analysis has uncovered/confirmed that statistical misinformation can result from even the best intentioned efforts to improve diagnostic criteria and staging. It would have helped for the release to connect the dots and demonstrate what those data are and what their impact would have on various patients.", "answer": 1}, {"article": "\"There was no doubt that eprotirome would lower LDL cholesterol. Thyroid hormone is nature's own statin,\" said Dr. Paul W. Ladenson, a professor of endocrinology and metabolism at the Johns Hopkins University School of Medicine and lead author of a report on the trial, published in the March 11 issue of the New England Journal of Medicine. \"But this is a demonstration of lipid-lowering effect without thyroid toxicity.\"\nFrequent monitoring showed no ill effects on the hearts and bones of those taking the drug, the report said.\nAt best, results would not be available for \"at least two to three years,\" Angelin said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t put this study into the context\u00a0 of other research on alternatives to statins. ", "answer": 0}, {"article": "Angioplasty remains the top treatment for people having a heart attack or hospitalized with worsening symptoms. But most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\nIt fixes only one blockage at a time whereas drugs affect all the arteries, experts said. Also, the clogs treated with angioplasty are not the really dangerous kind.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that stenting is not a new idea.", "answer": 1}, {"article": "The United States Preventive Service Task Force (USPSTF) currently recommends that physicians screen patients for dysglycemia (prediabetes or type 2 diabetes) when they are 40 to 70 years old and are overweight or obese. By following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened. The study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nThe study also touches on the financial implications of these guidelines. Under a provision in the Affordable Care Act, all services recommended by the USPSTF must be fully covered by insurers. But O'Brien said it is unclear whether insurers will be required to pay for diabetes screening if patients only meet the expanded criteria.\nOther Northwestern authors are senior author Dr. Ronald Ackermann and co-authors Mercedes Carnethon and Dr. Namratha Kandula. The other co-authors were from the CDC. Dr. Ronald Ackermann is the study's senior author.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study is the first to \u201creport on how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\u201d It also mentions that the research builds the study author\u2019s previous work. As noted above, the release should have included more hard data from the study to back up its argument. ", "answer": 1}, {"article": "\u201cIt\u2019s something you don\u2019t have to figure out,\u201d he said. \u201cPeople know what it is and where it grows. It\u2019s simple all the way around.\u201d\nThe fruit\u2019s appeal rests, in part, on this versatility. A single coconut produces water, nectar, flesh, milk and even textile fiber. That translates into a broad slate of products. And in contrast to another natural substance that gets transformed into a wide variety of products \u2014 petroleum \u2014 coconuts are viewed as healthy.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats. Instead of buying oils or supplements, just use the whole coconut.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story doesn\u2019t make it clear how novel coconut products are or whether they offer any benefits not offered by a regular, balanced diet or why.\u00a0There is certainly nothing new about coconuts. The story does not explain whether there is any new information that provides a rationale for increased attention to coconuts or whether the attention is fueled entirely by marketing.", "answer": 0}, {"article": "This article has been updated to include more information on DMAU.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nMore attractive to many men than a long-acting injection or topical gel\u2014both of which are in development\u2014the prototype pill offers a \u201cmajor step forward\u201d in male contraception, Stephanie Page, a professor at the University of Washington in Seattle and senior investigator on the study, said in a statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A 1980 journal article trumpeted \u201cChina Invents Male Birth Control Pill.\u201d 2003 saw the publication of a book titled \u201cThe Male Pill: A Biography of a Technology in the Making.\u201d As recently as 2016, news releases have talked about research such as \u201cmale birth control shots\u201d that \u201cprevent pregnancy\u201d (we reviewed that one). In short, research into pharmaceutical contraceptives for men has been an active field for decades \u2014 and premature announcements of breakthroughs date back at least 38 years. This story quotes a researcher involved in the recent study as saying the findings are a \u201cmajor step forward\u201d and are \u201cunprecedented in the development of a prototype male pill.\u201d But it doesn\u2019t tell us why. What makes this study, or this pill, different?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the popularity of knee replacement is expanding from older people to younger ones, suggesting that the operation is not new.", "answer": 1}, {"article": "\u201cThe No. 1 reason people don\u2019t continue it is the out-of-pocket expense,\u201d he said.\nBut the mask is like something from a bad science fiction movie: big, bulky and obtrusive. Many patients simply refuse to wear it or rip it off while asleep. Studies show that about half of all people prescribed C.P.A.P. machines stop using them in one to three weeks.\nNow an alternative form of C.P.A.P. is gaining popularity: a patch that fits over the nostrils. Called Provent, the patch holds two small plugs, one for each nostril, that create just enough air pressure to keep the airways open at night. It is far less intrusive than the traditional C.P.A.P. machine. It is also more expensive, and it doesn\u2019t work for every patient.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins by contrasting this new treatment with the existing treatment. It says \u201cFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing. C.P.A.P. reduces and in some cases completely prevents episodes of apnea. But the mask is like something from a bad science fiction movie: big, bulky and obtrusive. Many patients simply refuse to wear it or rip it off while asleep. Studies show that about half of all people prescribed C.P.A.P. machines stop using them in one to three weeks.\u201d The story makes the claim that the Provent patch is \u201cfar less intrusive than the traditional C.P.A.P. machine.\u201d The claim of novelty is not backed up by the evidence presented in the story or by any published clinical trial.\u00a0 As we noted above about one out of every six people using the Provent in the study stopped using it after 3 months.", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is not novel. Most readers likely know that nonoperative treatments such as pain medications and physical therapy are not new.", "answer": 1}, {"article": "\u201cTake charge of your biological clock,\u201d the invitation urged.\nSome reproductive specialists are enthusiastic. But others caution that Fertilome is just the latest genetic test promising more than it can deliver \u2014 and, in this case, playing to the fears of women who are anxious about becoming a mother. (Another example: a new $89 test that claims to tell women how their DNA could influence the level of a beneficial fatty acid in their breast milk.)\nSo a patient may see a table showing that her genetic variants make her twice as likely to have a condition known as recurrent pregnancy loss, defined as repeated miscarriages. But the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor. The doctor ordering the test, or a genetic counselor, is supposed to provide that information.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Many fertility clinics offer genetic testing. It is possible that Fertilome is unique to the extent that it looks for nearly 50 genetic variants. But the story doesn\u2019t clearly explain how this is different from other genetic tests that may be offered to help couples conceive.", "answer": 0}, {"article": "Currently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs. These include Prozac, Paxil, Zoloft and Lexapro. They work by improving levels of the hormone serotonin, which may be too low in people suffering from depression.\nFRIDAY, Dec. 7, 2012 (HealthDay News) -- An experimental antidepressant that targets the brain in a different way appears to both act fast and last long, researchers say.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression. Given the results so far, he said, people won't need to take the drug every day, only once a week or less.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is also a mixed bag. The story got rid of some of the more scientific jargon that was included in the press release, but in the process, some bits became ambiguous. Establishing novelty is one example. This is a novel approach; no drugs on the market have the same mechanism.\u00a0 There is intense interest in this field by the National Institutes of Health. The story states, \u201cMoskal\u2019s team developed a new way to target the brain\u2019s NMDA (N-methyl-D-aspartate) receptor\u2026\u201d but in fact, other antagonists, such as the anesthetic ketamine, work in a somewhat similar fashion.\u00a0 GLYX-13 targets brain receptors responsible for learning and memory, which is a different approach from most popular antidepressants that work by improving levels of the hormone serotonin. Although pieces of this information are stated in the article, this does not clearly come across to the reader. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "But raloxifene did not prevent two other serious breast conditions, whereas tamoxifen did reduce their risk by 50 percent. Those conditions, sometimes called noninvasive breast cancers, are L.C.I.S. and D.C.I.S., for lobular and ductal carcinomas in situ. Lobular growths increase the likelihood of invasive cancer, and ductal ones can become invasive. D.C.I.S. is often treated like breast cancer, with surgery and radiation.\nBut since there is no way to predict who will actually get cancer, everyone has to be treated, meaning that 980 will be exposed to the drug's risks but will get no cancer benefit.\nBut Dr. Ford of the cancer institute said raloxifene's ability to prevent invasive cancers was more important.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that raloxifene is an existing drug but that Eli Lilly is asking the FDA to approve it for another purpose.", "answer": 1}, {"article": "Professor Arne Astrup, MD, DMSc \n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen. \"The beauty of this concept is its simplicity. While we are looking into other biomarkers, it is quite amazing how much more we can do for our patients just by using those two simple biomarkers. We will continue to participate in and support research to explore additional biomarkers such as gut microbiota and genomics approaches, which may offer more insights and help to more effectively customize the right diet for specific individuals.\"\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN). Presented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study. The different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that vegetables, fruits, whole grains, and healthy fats should be recommended for weight loss is hardly new. And yet the release frames these results as \u201cpotentially [leading] to a breakthrough in personalized nutrition.\u201d We\u2019d need more proof of tangible benefits before agreeing with that characterization.\u00a0", "answer": 0}, {"article": "Smoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year. The smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\nStill, some researchers not involved in the study said the topic required more work.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo. \u201cBut the findings from one study do not make a fact. We need more studies, funded by someone other than the company that makes the product.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that gradually cutting down on smoking, with the help of patches and gum, is an established way to change habits. However, it suggests that the current study \u201cis the first that appears to show the same for pills,\u201d which is not entirely accurate. As noted above, the competing drug\u00a0bupropion has been studied in this context and shown to offer potential benefits. Since this is essentially the same problem that we noted above under \u201cAlternatives,\u201d however, we won\u2019t penalize the story again for this omission.", "answer": 1}, {"article": "Acupuncture has been used for more than 2,000 years in Chinese medicine to treat a wide variety of ailments. According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story described the use of acupuncture for treating patients with chronic pain, but it did not mention previous studies that evaluated its use in depression. ", "answer": 0}, {"article": "Standard therapies include over-the-counter pain meds, corticosteroid spinal injections, and/or invasive spine surgery that sometimes involves disk removal and vertebrae fusion.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nNevertheless, he remains unsure if pRF is truly ready for prime time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains early on that pRT is \u201cnot new\u201d although it\u2019s claimed that recent technology advances enable doctors to deploy it with better accuracy.", "answer": 1}, {"article": "Currently, an early Alzheimer's diagnosis requires complex brain scans. Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The broadcast did lay out for viewers that currently, it is only after death that Alzehimer\u2019s disease can be definitely diagnosed and so if this test were demonstrated to be valid, it would represent something new.", "answer": 1}, {"article": "Approved to help smokers quit in 2006, Chantix (varenicline) has its share of potential side effects. In July 2009, the U.S. Food and Drug Administration mandated that Chantix carry a \"black box\" warning about the potential risks of depression and suicidal thoughts. Recently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease. Chantix costs roughly $3 per pill.\nWEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned above, other drugs are already used to treat alcohol addiction. Readers of this story should have been given that background.", "answer": 0}, {"article": "The most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nKnown as sublingual immunotherapy, the treatment relies on the same principles as traditional allergy shots, but is delivered by tablets or drops that dissolve under the tongue.\nFor the new study, reported in the Journal of Allergy and Clinical Immunology, Italian researchers combined the results of 19 clinical trials conducted since 1995 on the effectiveness of immunotherapy tablets and drops against hay fever caused by grass pollen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nBy mentionsing that trials from 1995 were included in the meta-analysis, the story lets readers know that sublingual allergens are not novel. The concept of administering allergens orally has been proposed as early as 1900. \n", "answer": 1}, {"article": "Sufferers can also opt for localized surgery, like liposuction, to remove or injure sweat glands. Oral medicines can be used to systemically limit sweating. For instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no unfounded claims about novelty, and the story makes it clear that an effective topical treatment via wipes would be new for this condition.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This ties in to what we said above regarding alternatives. By explaining several surgical interventions that address uterine fibroids, the story clearly articulates what is novel about the Sonata approach. Well done.", "answer": 1}, {"article": "Cochlear implants that have electrodes designed without wire perform better than those with wires for long-term hearing preservation, a Mount Sinai researcher has reported in a first-of-its-kind study. The research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear. The results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n\"The cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\" said Dr. Wanna. \"Our results also revealed that using oral steroids also helped in the long term to preserve hearing by preventing inflammation.\"\n\"We hope the findings will help surgeons choose the best implants and approaches for their patients,\" said Dr. Wanna. \"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t tell us anything about the novelty of the wireless cochlear implants nor that of the \u201cround window\u201d (where surgeons open the membrane without bone removal or drilling in the inner ear) and \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear). \u00a0Are these new procedures? \u00a0What other research has been done on them? \u00a0Where is the context that establishes the place of these in the current landscape of hearing-preservation technologies?", "answer": 0}, {"article": "Ellis also is a McNair Scholar at Baylor.\n\"We launched a phase II clinical trial of neratinib in patients with metastatic breast cancer carrying a HER2 mutation,\" Ellis said. \"Finding patients that are positive for a HER2 mutation required a national collaboration because we had to screen hundreds of patients to identify the 2 to 3 percent that have a tumor driven by a HER2 mutation. The results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression. Neratinib was well tolerated by most patients.\"\nThe number of patients who could potentially benefit from this new treatment approach is estimated to be in the thousands. The researchers estimate that as many as 200,000 patients are likely to be living with metastatic breast cancer today in the United States. Based on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release made it seem that neratinib was an experimental drug that could be used for women with a particular gene mutation related to HER2+ metastatic breast cancer. It wasn\u2019t made clear that neratinib is already used to treat early-stage HER2+ breast cancer.", "answer": 0}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t establish novelty. The implication is that the approach is new, but is this the very first time that such a strategy has been tested? If so, where did the idea come from? If not, what did previous studies of this approach find? A bit of background would have been useful.", "answer": 0}, {"article": "About 80 percent of hemophilia cases are of the type known as hemophilia A, which is caused by defects in a different blood-clotting agent, Factor VIII. Researchers have focused on hemophilia B, in part, because the Factor IX gene is much smaller and easier to work with.\n\u201cWe attribute this to the fact that he had an inflammation, and although we treated it promptly, we should have been quicker off the mark,\u201d Dr. Tuddenham said.\n\u201cI don\u2019t think it\u2019s a showstopper, but it\u2019s a critical safety issue that has to be assessed,\u201d Dr. High said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach \u2013 both for what it apparently achieved \u2013 and for how it builds on past research \u2013 was clear in the story.", "answer": 1}, {"article": "Lung cancer is the leading cause of cancer death. The American Cancer Society (ACS) estimates that more than 224,000 Americans will be diagnosed with lung cancer this year, and more than 158,000 lung cancer patients will die\u2014that translates to 433 lung cancer deaths per day in the United States.\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel. \u201cThe technology is pretty robust. Our next step is getting approval from the FDA.\u201d\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a strong claim of novelty \u2014 and that\u2019s appropriate.\nA quick online search found that besides this research from the University of Louisville in Kentucky, at least two other institutions are developing breath tests for lung cancer detection: Georgia Institute of Technology and the Winship Cancer Institute of Emory University\u00a0 and the University of Leicester.\nThe release said \u201cA subset of four VOCs\u2014called carbonyl compounds because of their carbon base\u2014have been discovered in the exhaled breath of lung cancer patients.\u201d Discoveries sound novel. But this study, more than a decade old, describes the use of VOCs for lung cancer detection. \nWhile the release doesn\u2019t claim to be \u201cfirst,\u201d it might have mentioned related work that has been done in this field of research.", "answer": 0}, {"article": "Learn more about insomnia and good sleep habits from the National Sleep Foundation.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\n\"The way [suvorexant] works makes a lot of sense,\" Bazil said. \"The hope is that it will help some people who haven't responded to [other drugs], and have fewer side effects.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One of the independent experts addressed the drug\u2019s relative novelty in this section:\n\u201csuvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\n\u201cThe way [suvorexant] works makes a lot of sense,\u201d Bazil said. \u201cThe hope is that it will help some people who haven\u2019t responded to [other drugs], and have fewer side effects.\u201d", "answer": 1}, {"article": "Montmorency tart cherries are the most common variety of tart cherries grown in the U.S., and are available year-round in dried, frozen, canned, and juice forms - including juice concentrate, which was the form used in this human trial. Montmorency tart cherry juice concentrate can be mixed with water or other juices. It can also be consumed straight from the bottle or used as an ingredient in recipes, such as smoothies and other beverages.\nThis study was made available online in April 2018 ahead of peer-review and publication this month.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions the study is \u201ca first-of-its-kind trial\u201d of humans combined with a parallel laboratory study.\nIt\u2019s mentioned in the published study that, to the authors\u2019 knowledge, this is the \u201cfirst microbiota/metabolome investigation of the impact and fate of tart cherries and their polyphenols in the human colon.\u201d", "answer": 1}, {"article": "\"In this subset of women experiencing multiple early miscarriages, we assume that their embryos were literally starving to death,\" Kliman added. \"They attached, but they were not getting enough food. When we give progesterone back to these women, the endometrium makes more nutrients and prevents their pregnancy loss.\nFetal death, or intrauterine fetal demise (IUFD), affects 30,000 women each year in the United States. About 25% of all women who become pregnant have a first-trimester loss. But for some women, every pregnancy results in a loss. The researchers studied the effects of micronized plant-derived progesterone in 116 of these women who had experienced two or more pregnancy losses.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release doesn\u2019t establish the novelty of this approach. Other research studies have looked at the use of progesterone in preventing miscarriages.\nAccording to the reference site \u201cUpToDate\u201d by medical publishers Wolter Kluwer, more than 50 research studies have examined the use of progesterone in preventing miscarriage or pre-term birth, with mixed results.", "answer": 0}, {"article": "Knee braces basically help realign the knee; taking pressure off of damaged areas to relieve pain and restore function. Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing. The study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities. And by and large, they did. Their quality of life improved, and their activity level went from one that did not permit recreational sports to one that did.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The braces studied were appropriately not portrayed as a new treatment approach.", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nTwo HPV vaccines are now approved by the FDA: Cervarix and Gardasil. Both of these vaccines are recommended to prevent cervical cancers. These vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts. The vaccine is recommended for optional use in boys and men. The vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good history and context given about the two vaccines \u2013 Gardasil and Cervarix. Better than competing HealthDay on this count.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research.", "answer": 1}, {"article": "PCA3 is found only in the prostate. When prostate cells become cancerous, their PCA3 genes go crazy. Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nAt a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, researchers presented results of the largest study to date of the PCA3 test. It showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0This story failed to mention that peer reviewed studies examining the utility of PCA3 have not found it to be significantly associated with progression of prostate cancer.\u00a0 Reporting on the results of this recent study, based on information from a company spokesperson without examining what others may have found to date is inadequate.\n", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The focus of the story is IVM as a newer method of fertility treatment.\u00a0 The story is clear that there have not been many births from this method. ", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly notes that these techniques were originally developed for use in brain surgeries, but are now being considered for use in a variety of other procedures \u2014 and have been since at least 2011.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that researchers are exploring a new use of an existing product.\u00a0 ", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that CAD is a newer method of reading mammographies, but in a recent observational trial it was no better\u2013and may have produced more false positives\u2013than images read and interpreted by radiologists alone.", "answer": 1}, {"article": "HER2-positive breast cancer tests positive for a protein known as human epidermal growth factor receptor 2, or HER2, which promotes the tumor cell growth. About one of every five breast cancers involves cancer cells that churn out an excess of HER2 due to a genetic mutation. HER2-positive breast cancers are often more aggressive than other types, according to the American Cancer Society.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study\u201d but didn\u2019t explain how the vaccine in question is different than any of those other approaches.", "answer": 0}, {"article": "\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers. Nearly all cancer patients require monitoring by whole body imaging, which can be costly, complex, and time-consuming. In contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread. Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\nThe report describes the use of the test to analyze samples from six patients. Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients. In one patient, the assay was able to show the presence of three different mutations. The three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty here:\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Promoting growth hormone to counteract the effects of aging, namely physical functioning, is not new. However, the benefit of this has not been established and safety of growth hormone for this use in older adults in unknown. The story does note that this study does not represent a breakthrough in preventing age-related decline in physical or cognitive functioning. ", "answer": 1}, {"article": "Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the \"Actavis plc\" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.\nTrueTear\u2122 provides a temporary increase in tear production during neurostimulation in adult patients.\nTrueTear\u2122 is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears. There have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this is the first neurostimulator intended to increase tear production in patients with dry eye problems.", "answer": 1}, {"article": "They turn out to have little effect on kinematics \u2014 the actual movement of the skeleton during a run. But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nBeing generous about studies with design flaws that could overstate effects, Dr. Nigg and his colleagues concluded that custom-made orthotics could help prevent and treat plantar fasciitis, a common injury to a tendon at the bottom of the foot, and stress fractures of the tibia, along the shin. They added, though, that the research was inadequate for them to have confidence in those conclusions.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The shoe inserts described in this study are widely available and are not particularly novel in concept or design. The article did not \u201chype\u201d particular orthotics because of innovative characteristics or qualities.\n\u00a0\n", "answer": 1}, {"article": "The use of complementary and alternative medicine for the management of menopause symptoms has surged in recent years as women have attempted to identify alternatives to hormone therapy (HT). Although HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects. Fennel, an herb containing essential oils, has phytoestrogenic properties. Phytoestrogens are estrogen-like chemicals in plants that have been used to effectively treat a wide array of menopause symptoms.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS. \"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nCLEVELAND, Ohio (May 17, 2017)--Fennel, an anise-flavored herb used for cooking, has long been known for its health benefits for a variety of issues, including digestion and premenstrual symptoms. A new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects. The study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook here is that results of this\u00a0study are billed as \u201cconfirmation\u201d of benefits \u2014 an overstatement \u2014 but also that the study is one of the first undertaken with scientific rigor. It\u2019s hard to say if that is so, but the release makes a reasonable case, albeit based on a very brief trial.", "answer": 1}, {"article": "\u2022 the item no longer exists, or\n\u2022 select an item from our site index below\n\u2022 there has been an error on the site.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Described within this story as \u2018a new device\u2019 and that \u2018about 100 hospitals around the country already are using the treatment\u2019 which suggest that this is a relatively new approach.", "answer": 1}, {"article": "To see whether children with epilepsy would benefit from cannabidiol treatment, Devinsky led a study involving 261 people, mostly children, whose seizures had not been controlled using current anti-seizure medications. The average age of the participants was 11.\nEveryone received a British-made cannabidiol oil called Epidiolex, which was administered as a drop on the tongue, Devinsky said. This was in addition to their current drug therapy.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since cannabis has been used for the treatment of seizures for centuries, it\u2019s curious why the researchers didn\u2019t test the compound in a better designed trial (randomized, blinded and placebo controlled). The public and patients are still left with the question of whether this works. But the story does briefly mention previous studies that have looked at cannibidiol in adults, so the story gets a pass here.", "answer": 1}, {"article": "The U.S. National Institutes of Health has more on acupuncture.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It would be pretty novel if the study had shown that acupuncture was more effective than conventional analgesic drugs in controlling pain, but that\u2019s not what this study showed. While\u00a0both the study and the story\u00a0did seem to indicate that acupuncture was as effective as either painkillers or painkillers and acupuncture, the\u00a0abstract of the study\u00a0also said \u201cnone of the examined therapies provided optimal acute analgesia.\u201d Controlling pain was arguably the reason the study\u2019s patients went to the emergency departments. The study basically said acupuncture was as good as painkillers for pain control but that for these patients, neither was successful. We think that should have been explained in the story to help establish the novelty of this research.", "answer": 0}, {"article": ", said each woman must decide for herself, with full knowledge of the pros and cons, whether to perform self-exams. And there's not a right or wrong answer. Some may do the exams and accept the risk of unnecessary biopsies, she said. Others may decide that either they can't commit the time to do them right, or that the potential for false alarms and anxiety isn't worth it. \"That's a very personal decision,\" Steiner said.\nEven though her mammogram showed no sign of cancer, Sandra Litt knew she could feel a lump. She had a second mammogram. Nothing there, the radiologist assured her. \"Then one night, I found the 'nothing there' had grown bigger,\" Litt said. Her self-exam had proved accurate. Two years ago, Litt underwent a double mastectomy and months of chemotherapy to survive an aggressive breast cancer. It defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good. \"It's a very important tool,\" the 67-year-old Portland woman says. \"Why throw away an important tool?\" A scientific review, published in August by the\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies. They are about twice as likely to undergo biopsies that won't find cancerous tumors, according to two studies tracking hundreds of thousands of women in China and Russia. Conflicting news coverage has heightened the confusion. \"Breast self-exam has no benefit,\" one headline proclaimed. \"Breast self-exam key in catching what mammogram may miss,\" another said. What is clear is that studies don't supply an answer that fits all women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Breast self-exam is not novel; neither are the recommendations being discussed. The story explains how public health education campaigns influenced the widespread promotion of BSE for every woman, and that such recommendations are no longer appropriate based on available evidence. ", "answer": 1}, {"article": "Scientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development. Several studies indicate that babies born prematurely receive too little DHA, and some studies have found that premature babies fed DHA after birth show better cognitive performance or visual coordination later on than preemies who aren\u2019t given DHA.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants,\u201d he said. \u201cAnd it might be of some help.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The past research on this topic was made clear. ", "answer": 1}, {"article": "They found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nSUNDAY, July 19, 2015 (HealthDay News) -- It's still very early, but scientists say a test based on a patient's saliva might someday help detect Alzheimer's disease.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research discussed here is novel in a general sense, but the story doesn\u2019t establish this to a satisfactory degree. A number of previous studies have looked at saliva markers of Alzheimer\u2019s, and there are probably dozens of other blood tests, scans, and other approaches currently in development to address the diagnosis of Alzheimer\u2019s disease. The story does not allude to this research", "answer": 0}, {"article": "For decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids). The difference came down to the specific type of fats that make up these foods \u2014 animal and dairy fats tend to be saturated, which means all of the free bonds available in a chain of carbon atoms are bound to hydrogen atoms, while plant fats are unsaturated, meaning some of carbon atoms have double bonds with each other. Saturated fats are more likely to build up within artery walls and form plaques that can trigger heart attacks.\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\nA study shows that not all good fats are the same when it comes to protecting your health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the mortality findings of this study were previously reported in 1978, and that the cardiovascular findings are new. That\u2019s more detail than HealthDay provided.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cThe basis of autism in the brain is very deep. There may be very little that one can actually change about the disorder for an individual with a severe case,\u201d Lange said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the test is unclear from this story. Diffusion tensor imaging is not new and it has been used in previously published reports, a fact not provided to the reader. The way in which it was used was new and novel. We usually take people to task for suggesting a drug or medical device or procedure is novel when it is perhaps not. The story should have indicated that although the scanners used were conventional and others have employed the technique described, the programming is novel and not routinely available.", "answer": 0}, {"article": "For more on implantable devices, visit the American Heart Association.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of these devices or of remote monitoring is never established. The story also could have established the relative novelty of the dataset.\u00a0 The manufacturers\u2019 patient registry allowed the researchers to study the real world events in people living with ICD\u2019s and CRT-D\u2019s. The story does not note the rather unique circumstances allowing the research to be conducted; a manufacturer\u2019s patient registry.", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death. Even though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later. The high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that using a follow-on booster of the high-dose vaccine is a novel flu prevention strategy in patients with cancers that affect the immune system. This approach of adding a booster is used in immune-suppressed patients with\u00a0other vaccines as well.", "answer": 1}, {"article": "The researchers found that a troponin threshold of <5 ng/L at presentation identified around two-thirds (61%) of patients at very low risk of heart attack and may have been eligible for early, safe discharge--with a high negative predictive value of 99.6%. This high negative predictive value persisted irrespective of age, sex, cardiovascular risk factors, or prior cardiovascular disease. At one year, these patients had a three times lower risk of heart attack and cardiac death than those who had troponin levels 5 ng/L or higher.\nThis study was funded by the British Heart Foundation and Chief Scientists Office (Scotland).\nAccording to Dr Shah, \"Over the last two decades the number of hospital admissions due to chest pain has tripled. The overwhelming majority of these patients do not have a heart attack. This study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department. Use of this approach is likely to have major benefits for both patients and healthcare providers.\"[2]\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook for this release is pretty well established.", "answer": 1}, {"article": "Letrozole is available as a generic for less than $100 a month.\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study. But because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years. There had been no research on whether that was beneficial.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately establishes the novelty of the study:\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\n\u201c\u2026If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\nThis is important because many patients already continue aromatase inhibitors:\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years. There had been no research on whether that was beneficial.", "answer": 1}, {"article": "For more about prostate cancer, visit the U.S. National Library of Medicine.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\nIn the study, researchers followed 14 men who were taking hormone therapy for prostate cancer and suffered from hot flashes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No context was given for placing this research into the bigger picture of what else is doing for the hot flash problem, or if other related acupuncture research has been done.\nA study (Harding C, et al) was published in the British Journal of Urology International in January 2009, reporting on a larger pilot study of 60 men with advanced prostate cancer who did show substantial symptomatic improvement. Those authors called for randomized trials to more definitively determine benefit.", "answer": 0}, {"article": "Nima is triangular and relatively dainty, about three and a half inches tall by three inches wide, and a little less than an inch thick. \"Small enough to fit into your pocket along with your keys and mobile phone or a small clutch,\" said Sundvor.\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website. The company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not the only product under the sun designed to quick-test for gluten, although to be fair, it\u2019s unclear whether another product would be better/worse/as good. A quick online search identified\u00a0a number of consumer kits available. It is unclear why a story focusing specifically on this particular device is news.", "answer": 0}, {"article": "It attacks and breaks down a naturally-occurring protein in the body which normally prevents cancer cells from spreading.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says, \u201cSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\u201d Quoting the author, though, does not prove that the approach is novel.\u00a0The study itself also says that the findings are novel: \u201cSignificantly, this is the first report of an interdependent biological role for distinct HECT E3 ubiquitin ligase isoforms, and highlights an entirely novel regulatory paradigm that selectively limits the level of inhibitory and activating Smads.\u201d Of course, that would not make much sense to most readers. So the story should have found a way to explain to readers why the approach to cancer treatment identified was a true advance that opened a new world of possibilities or whether it was a small improvement. And having an independent source evaluate the novelty would have helped as well.", "answer": 0}, {"article": "Neurosurgery, the Official Journal of the Congress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration. The study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups. The implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release identifies the study as the first randomized trial of a surgical procedure versus conservative,non-surgical care for SIJ dysfunction.", "answer": 1}, {"article": "By contrast, surgical cancer removal often means several hours in the operating room, complications of general anesthesia and weeks or months of recovery. Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nCryoablation is well-established in the treatment of liver, kidney, prostate and other cancers. Its effectiveness in breast cancer has been proven in a number of smaller studies, including a recent American College of Surgeons Oncology Group (ACOSOG) trial and extensive long-term ongoing, unpublished studies in Japan. The ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer. Patents will be followed for five years to ensure they remain cancer free.\nMEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine. A nick of the skin, a flash of cold and 25 minutes on an exam table. For thousands of women, this may soon replace surgery as a treatment for breast cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Breast cancer isn\u2019t normally treated with cryoablation, and the release makes this clear. We\u2019re also told the improvements built into ICE3 makes treating cancer with it \u201cmore precise\u201d and reliable.", "answer": 1}, {"article": "In January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease. At the time, Colorado was one of only about a dozen states in the U.S. that had legalized medical cannabis. It also allowed sick children to access the drug under professional guidance. Landon became the youngest patient in the U.S. at that time to receive a medical marijuana card. Riddle\u2019s decision to treat her child with cannabis landed the family in the center of a contentious national debate, as well as on prime-time television with CNN\u2019s chief medical correspondent, Sanjay Gupta. In Utah, all cannabis is illegal, so when their story went public, she and Landon had to move permanently to Colorado, so he could continue to have access to the drug. Even now, at 7, he still needs to take cannabis to cope with the long-term effects of chemotherapy and radiation, she says.\nRELATED: What we know about how cancer starts could all be wrong\nWhen Riddle made the decision to give her son cannabis, the information on its safety and efficacy was (and still is) limited to anecdotal accounts, a handful of case reports and lab studies published in obscure medical journals. Initially, her hope was that the drug would lessen the side effects. But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death. The theory seemed to be especially promising for leukemia, at least according to studies done on cancer cells in test tubes and on mice injected with human leukemia cells. But at that point there wasn\u2019t any evidence it would work for humans. There still isn\u2019t. While cannabis is legal in many U.S. states, the drug is still classified by the Drug Enforcement Administration as a Schedule 1 narcotic (along with heroin and cocaine), which make it very difficult for scientists to conduct clinical trials on people. However, that may change as other nations, such as Israel, take the lead and fund marijuana research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that people have been using marijuana, including cannabis oil, to treat symptoms and side effects of cancer treatment for some time now. It notes that hypotheses about a direct effect on cancer are relatively new\u2026 and remain to be tested in people.", "answer": 1}, {"article": "Researchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain. Patients were randomly assigned to 12 acupuncture sessions or 20 one-to-one Alexander Technique lessons plus usual care, or usual care only. Neck pain was assessed by the Northwick Park Questionnaire (NPQ) at 3, 6, and 12 months.\nNote: For an embargoed PDF, please contact Cara Graeff. To speak with the lead author, Dr. Hugh MacPherson, please contact David Garner at david.garner@york.ac.uk or +44 (0) 1904 322153.\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone. The study is published in Annals of Internal Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "What\u2019s novel about this study is the longer term relief gained from the therapies. The study points this out, but the release doesn\u2019t explicitly mention it.", "answer": 0}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking. And the group of people most at risk for social jet lag? Teens.\nIn all, the researchers call for more rigorous data on the topic. As schools change their start times, they write, researchers should sweep in to collect information on students\u2019 sleep in a standardized way.\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The reader will learn that the effects of eight or nine hours of sleep a night on teenagers have been demonstrated in other studies. What is novel is the meta-analysis\u2019 reflections on the big picture, which suggests caution in\u00a0making school policy changes on the basis of extant studies.", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects. It dwindles naturally with aging, which has been linked to declines in memory and executive function.\nAn expert who wasn\u2019t involved in the research echoed the cautions.\n\u201cIs it going to work in the long run and is it going to be safe? That is still unknown,\u201d said Petersen.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We think there could have at least been a line in the story about whether this is groundbreaking research looking at GHRH and mental function or whether there\u2019s been some track record.", "answer": 0}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD. \u201cIf this is the case, dosage shouldn\u2019t matter. But that is not what we found.\u201d\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is this odd quote in the story from the study author. \u201cObviously this is just one study, and it is observational,\u201d he says. \u201cBut if these findings are confirmed, this is pretty profound.\u201d This could have been a great opportunity for the reporter to explain what he means by an observational study and how much, much, much more work on a much larger group of patients would be necessary before statins could be safely recommended as a cancer treatment. Instead, the quote just ends on a positive note.", "answer": 0}, {"article": "\"We're not training them on one skill, like doing crossword puzzles,\" she says. \"We're embedding complexity and novelty into their daily lives, something that tends to disappear once people retire. The same things that benefit us at 5, 10, 25, 35 - contact with others, meaningful work - are certain to benefit us as we age.\"\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nThe research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study concept \u2014 a randomized controlled trial of a civic engagement program \u2014 is novel and builds upon findings from a smaller pilot study. However, the release doesn\u2019t establish what is new or different about the study compared with previous research.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the test is similar to the company\u2019s genetic test to identify more lethal breast cancers, yet that it is the first such test for colon cancer. ", "answer": 1}, {"article": "(Reuters) - Merck & Co\u2019s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.\nThe U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer. Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explain, in broad terms, the novel way in which Keytruda and a competing cancer immunotherapy drug, work. The story also talks about the expected economic impact of cancer immunotherapies broadly. So we\u2019ll give the benefit of the doubt on the rating. However, it\u2019s not clear how many cancer immunotherapy drugs are on the market \u2014 just these two? A dozen? More? The story also doesn\u2019t tell readers how many of these drugs are approved for use against lung cancer. Is it just Keytruda?", "answer": 1}, {"article": "\"He was getting into fights. He wasn't doing his homework. He was being very difficult with his little brother. And he was just melting down day after day,\" Ellison says. \"So I decided to devote a year to trying out different approaches to see if we could make it any better.\"\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not oversell the novelty of neurofeedback for the treatment of ADHD.", "answer": 1}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nSuch research is already underway, Arnold said, but it's too early to discuss the findings.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "N/A", "answer": 2}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Recommended pneumonia vaccinations in older adults and those with compromised immune and respiratory systems is not new.\u00a0 The story focused on new recommendations that all adult smokers be vaccinated. ", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this is the first trial to show a reduction in major cardiovascular events among patients taking this type of fish oil derivative.", "answer": 1}, {"article": "About 57 million Americans have prediabetes, a disorder marked by blood sugar levels that are elevated but not sufficiently high to be considered diabetic. Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nThe National Institutes of Health, plus the Diabetes Research and Training Center and the Institute for Translational Medicine at the University of Chicago funded this study. Additional authors include Kristen Wroblewski, Magdalena Stepien, Khalid Sharif-Sidi, Jennifer Kilkus and Harry R. Whitmore from the University of Chicago.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea. Two-thirds of them (26) were randomly assigned to two weeks of CPAP treatment. The other 13 received a placebo -- a pill containing no medicine -- to be taken 30 minutes before bedtime. They were told the study would compare the two treatments.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is one of the main limitations of the release. An online search shows that a number of studies have been done on the impact of CPAP use on patients with prediabetes and on patients with type 2 diabetes. The news release does not make clear how this most recent paper expands on the previous work \u2014 and it is important for releases like this one to place the new study in context.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nBronchial thermoplasty is indeed a relatively new approach to treating asthma. However, almost all of the trial results reported in this story were announced more than a year ago. The news is that the researchers recently presented results from the second year of follow-up at a medical meeting. However, the new information was barely mentioned in the story.", "answer": 1}, {"article": "\"We show that patients taking anticoagulant [blood thinning] medication had better outcomes with regards to prostate cancer death and that this benefit was most prominent in patients who had high-risk disease,\" said study lead author Dr. Kevin Choe, a radiation oncologist with the University of Texas Southwestern Medical School in Dallas. High-risk tumors are more aggressive and thus more likely to eventually kill the patient.\nMONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\nThe study included 5,275 men diagnosed with prostate cancer that had not yet spread beyond the prostate gland and had been treated with surgery or radiation. Of the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story notes that lab tests and other clues about cancer and blood coagulation have suggested that anticoagulants might have some effects, but that there has been little work that looks at these questions in people who have tumors that have not spread beyond the prostate.", "answer": 1}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article explains that this type of study had been conducted before with the WHI.\nBut we would have hoped for a little more explanatory background and context.\u00a0 The article doesn\u2019t adequately address the point that it is a novel study, because it looks specifically at early menopausal women and effects of hormone therapy on blood vessels \u2013 a not unreasonable early surrogate for harder endpoints such as CV disease events. The findings are actually not novel. The WHI analysis of a subset of younger menopausal women, published in 2007, showed that there was less coronary artery calcification in women treated with Estrogen and Progesterone compared with those who took placebo; a finding the KRONOS researcher thought they would also see, but did not. (They report a nonsignificant trend toward less calcification).", "answer": 0}, {"article": "This study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals. Unlike deep brain stimulation, dTMS does not need an operation or implantation of electrodes. Instead, an electromagnetic coil is placed on the scalp and sends magnetic pulses to stimulate specific deep regions of the brain. Currently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nThe research team also measured blood levels of glucose (sugar), insulin, pituitary gland hormones and neurotransmitters such as norepinephrine. Pituitary hormones play a key role in regulating appetite, and recent research shows that norepinephrine and other neurotransmitters affect microbiota composition, Luzi said.\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release confirms that dTMS has been around for a while and is used to treat other conditions, but highlights that using the procedure to treat obesity is a new area of exploration.", "answer": 1}, {"article": "The results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least. No link between overall flavonoid consumption and Parkinson\u2019s disease risk was found in women.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease. This was an observational study and therefore can\u2019t establish cause and effect. Nor is it clear why the results differed for men and women.\nThis study will be presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story allows the researcher to claim that \u201cthis is the first study in humans to examine\u201d this association.\u00a0 We don\u2019t know whether that\u2019s true or not.\u00a0 And the story didn\u2019t provide any independent perspective to reflect on whether this is novel or not. But there\u2019s been a lot of other flavonoid research which the story could have at least mentioned.\u00a0 From this story, one might assume that this is the first study that\u2019s ever recognized flavonoids.", "answer": 0}, {"article": "MEN, the joke goes, spend the first half of their lives making money and the second making water. That is because after age 50 many men face an embarrassing problem called B.P.H., for benign prostatic hyperplasia. This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons. \u201cHowever, he developed urinary tract infections annually because of his B.P.H. and almost died from sepsis one year. Surprisingly, his case is not unique.\u201d\nThough bothersome, B.P.H. is not life threatening. Nor does it lead to cancer. When left untreated, however, B.P.H. can lead to serious health problems for some.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did an acceptable job laying out the currently available approaches to BPH management; it also mentioned research with Botox for use in treating BPH as well as the novel use\u00a0of erectile dysfunction drugs for treating BPH.", "answer": 1}, {"article": "About the European Society of Cardiology\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly. Based on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality. In this meta-analysis a low dose of activity resulted in a mortality rate reduction of 22%.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been numerous studies on the benefits of exercise for the general population. Physicians currently recommend exercising for 30 minutes a day for at least five days a week, which \u201chas been shown to reduce the average risk of death by 30%,\u201d according to an uncited source in the news release.\nWhat\u2019s new, says the news release, is that \u201ca correlation between the level of physical activity and risk of death has not been so clearly determined in the elderly.\u201d\nBut we found these studies online, some going as far back as 1989, that state the association between regular physical activity and decreased mortality in older adults. In addition, recommendations are already in place for older adults, who are urged to exercise moderately and daily by the CDC.\nWe\u2019re not sure why the physical activity recommendations for the elderly warrant revision, as stated by the release, or what exactly is new with this research.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nSaying the study was \u201cof critical importance,\u201d Dr. R. Sean Morrison, president of the American Academy of Hospice and Palliative Medicine, said it was the \u201cfirst concrete evidence of what a lot of us have seen in our practices \u2014 when you control pain and other symptoms, people not only feel better, they live longer.\u201d\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "By all accounts, this is the first randomized controlled study to show that providing palliative care\u00a0early after a\u00a0diagnosis of advanced cancer improves survival and other outcomes. The story accurately characterizes the significance of this. ", "answer": 1}, {"article": "Clinics in the U.S. have long frozen fertilized eggs, or embryos. But eggs alone are more delicate and prone to damage. Over the years, egg freezing has been offered mainly to cancer patients facing radiation, but success rates were pretty dismal. Of late, though, the technology has exploded thanks to scientific leaps, including a flash-freeze method called vitrification.\nThis story is part of an occasional series.\nCopperman explains the procedure, introduces someone who has gone through it and takes a flurry of questions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a decent job of explaining that the technique is experimental.", "answer": 1}, {"article": "IVM may also help women who have a contraindication to the increased levels of estradiol, a form of estrogen, which elevates as the follicles develop and mature. These would include women with an estrogen-sensitive cancer or a history of blood clots.\n\u201cWith medicine, you always want to optimize a patient\u2019s outcome,\u201d Shastri said. \u201cUltimately, you want to do the best for the patient so my preference would not be IVM.\u201d\nWho is IVM helpful for?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, it\u2019s hard to say just why Fox is presenting this as \u201cnews now.\u201d", "answer": 0}, {"article": "Unlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor. Using the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nNewswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the Savi Scout is novel and that Rush is the first institution in Illinois to deploy the technology.", "answer": 1}, {"article": "Nearly 7 million Americans have chronic wounds \u2013 typically a result of diabetes, obesity or other conditions that impact circulation \u2013 costing the healthcare system nearly $25 billion each year. The non-healing wounds are painful, can permanently damage nerves, prevent mobility and in extreme cases, cause infection that can lead to death.\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\nNewswise \u2014 Columbus, OH. Good news for the millions of people who suffer from skin wounds that won\u2019t heal. A team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As the news release points out,\u00a0FDA-approved\u00a0WEDs already exist on the market. What is the real novelty here? We are told:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\nBut the release never explains what these\u00a0significant advances are.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown. \"Typically, immune cells from solid tumors, called tumor-infiltrating lymphocytes, can be harvested and grown in only about 25 percent of patients who could potentially be eligible for the therapy. But in our clinical trial, we were able to harvest and grow MILs from all 22 patients,\" says Kimberly Noonan, Ph.D., a research associate at the Johns Hopkins University School of Medicine.\nOther Johns Hopkins scientists who contributed to the research include Carol Ann Huff, Janice Davis, M. Victor Lemas, Susan Fiorino, Jeffrey Bitzan, Anna Ferguson, Amy Emerling, Leo Luznik, William Matsui, Jonathan Powell, Ephraim Fuchs, Gary L. Rosner, C. Epstein, Lakshmi Rudraraju, Richard F. Ambinder, Richard J. Jones and Drew Pardoll.\nMILs, he explains, are the foot soldiers of the immune system and attack foreign cells, such as bacteria or viruses. But in their normal state, they are inactive and too few in number to have a measurable effect on cancer.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We like the fact that the headline itself defines this as a \u201cpilot\u201d clinical trial and that the lede says that it is \u201cwhat is believed to be the first small clinical trial of its kind.\u201d\u00a0 Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings.\u00a0 All too many other medical releases fail to provide this measured approach.", "answer": 1}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis. Hormone therapy may help relieve a woman's menopausal symptoms but is not recommended for women who have had breast cancer.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Besides listing lifestyle approaches which are not novel, it\u2019s unclear if the emerging approaches listed are novel.", "answer": 0}, {"article": "Beyond the screening question, many physicians routinely ask patients about their calcium and vitamin D intake. The federal government recommends just 400 international units daily of vitamin D for adults over age 50, while the National Osteoporosis Foundation recommends 800 to 1,000 units. Some doctors suggest doubling those higher amounts for post-menopausal women.\nWhen it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nDr. Felicia Cosman, clinical director of the National Osteoporosis Foundation and a professor at Columbia University, said the swirl of new information makes it critical for patients to review with their physicians their treatment decisions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article discussed management approaches to osteoporosis that are well established\u2014though in some cases uNPRoven. Discussion of their novelty wasn\u2019t necessary. ", "answer": 2}, {"article": "Not all women are eligible for ovarian tissue transplants, however. \"In particular, we have not performed transplants in patients who have suffered from leukemia, because the ovarian tissue may harbor cancer cells,\" Jensen said.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Apparently, it isn\u2019t new to remove an ovary and freeze it. Some of the patients in the study had that done 15 years ago. The story establishes this and explains that the study is new in that it reports on longer-term outcomes.", "answer": 1}, {"article": "Patients with small levels of arterial calcium had a 68 percent increased overall risk of death, compared to those with no calcium deposits at all. But people with the largest calcium deposits in their arteries had a death risk six times greater than those with no calcium.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\nThe findings appear in the July 7 issue of Annals of Internal Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story specifically notes that CAC testing is not new, and that previous research hasn\u2019t assessed long-term health risks associated with CAC.", "answer": 1}, {"article": "\u201cThere are economic, medical and psychological consequences of finding these abnormalities,\u201d Dr. Varmus said.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times. Had the screening continued for 10 years, as many as 80 percent of lung cancer deaths could have been averted, she said. Dr. Henschke\u2019s research has been controversial because of its statistical methods and its financing, which included money from a tobacco company. She earns royalties from makers of CT machines.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute. It involved more than 53,000 people ages 55 to 74 who had smoked at least 30 pack-years \u2014 one pack a day for 30 years or two packs a day for 15 years. Ex-smokers who had quit within the previous 15 years were included in the group.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story recaps some of the history of research on screening for lung cancer and quotes one of the researchers saying, \u201cThis is the first time that we have seen clear evidence of a significant reduction in lung cancer mortality with a screening test in a randomized controlled trial.\u201d", "answer": 1}, {"article": "Many patients suffering from Prader-Willi syndrome, the rare condition Beloranib treats, are prone to blood-clotting and other diseases. Hughes said Zafgen will continue to study the effect of the drug in its further trials and risk-mitigation plan, and address it in discussions with FDA officials.\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year. Zafgen has lost more than 80 percent of its stock value since the week in October when the first death was made public.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Having stated that there are currently no treatments for Prader-Willi, the novelty of the beloranib should be\u00a0self-evident to the reader.", "answer": 1}, {"article": "Melatonin significantly reduced BP. The hypotensive effect was dependent on time. The maximum systolic BP lowering effect of melatonin falls between 3:00 and 8:00 in the morning, the time of the highest risk of heart attacks and strokes. Nighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SBP/DBP, respectively.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships. The improvement of circadian pacemaker functions may also provide a new strategy in the treatment of hypertension.\nMelatonin ws effective in synchronizing disrupted circadian rhythms of BP, heart rate and body temperature, making these circadian rhythms smoother and less irregular. None of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t make a claim to novelty, but then it shouldn\u2019t as this study doesn\u2019t appear to offer anything new. Melatonin\u2019s main job in the body is to regulate night and day cycles or sleep-wake cycles. Many researchers have explored the\u00a0effects of melatonin supplements, and one 2010 review noted that its use was well established \u201cespecially\u201d for sleep disorders, including those related to aging.\u00a0 Much research has also determined that melatonin reduces night-time blood pressure levels in those with hypertension.", "answer": 0}, {"article": "These showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant. Overall survival was 14.4 months with Opdivo versus 13.2 months.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that these findings reveal that immunotherapy works better when patients are prescreened for a specific genetic marker known as PD-L1, versus giving it to anyone with this type of cancer. It also\u00a0explains that the smaller second trial, mixing Keytruda with chemotherapy, was \u201cthe first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\u201d", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Neither story was very clear on this point, but the WebMD story did not make a claim of novelty the way the AP story did. Contrast the two leads:\nWebMD: \u201cA new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\u201d\nAP: \u201cNew research offers hope for the first pill to treat a common problem in young women: fibroids in the uterus. The growths can cause pain, heavy bleeding and fertility problems, and they are the leading cause of hysterectomies.\u201d\nWe\u2019ll give a lukewarm \u201csatisfactory\u201d grade.", "answer": 1}, {"article": "Doctors run many different tests to assess someone\u2019s risk of heart disease. They measure cholesterol, blood pressure and heart rate, they test the electrical signals that keep the heart beating and they may also run imaging tests to check for clogged arteries.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on the use of inflammatory heart tissue as having potentially better predictive value than current risk assessment tools for heart attack. But it\u2019s a reluctant satisfactory, because the narrative is confusing and no\u00a0numbers were given to estimate the scope of the potential benefit\u2013how well the new approach worked.", "answer": 1}, {"article": "Roslin said limiting grains and sugars reduces insulin surges, which sparks water loss, curbs hunger and can boost energy.\n\"I feel pretty energetic and I'm not missing the meat. I'm not missing the coffee,\" said viewer Rose Marie Volpe, who tried out the plan.\nBut \"GMA\" viewer Janine Efron had less success while trying the Martha's Vineyard Diet Detox, which consists of shakes rich in antioxidants and proteins. Efron lasted only four days. Like many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There was actually no discussion about the history of the products highlighted in this broadcast other than to indicate that they are all the rage. \u00a0Are they new? \u00a0One could not discern this from the segment.", "answer": 0}, {"article": "Esler's team found that more than 83 percent of those who had denervation treatment before had a drop in systolic blood pressure of at least 10 mmHg after six months and almost 79 percent maintained the reduction at 12 months.\nMONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nThe procedure is safe as well as effective, the study authors said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story didn\u2019t reference any of the other of a growing list of other approaches to resistant hypertension.\u00a0 See some of our recent blog posts on this issue:", "answer": 0}, {"article": "The average hemoglobin A1C level dropped 1.06 percent for those with residual beta cell function and 1.68 percent for those without beta cell function. A1C levels measure average blood sugar levels over two to three months, and people with type 1 diabetes are advised to maintain A1C levels below 7 percent. A drop of 1 percent in A1C levels can reduce the risk of complications.\nResults of the study were published online Jan. 9 in the journal BMC Medicine.\nThis treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is clear that this treatment is a new approach.", "answer": 1}, {"article": "Dr. Jennifer Shu, a practicing pediatrician and CNNHealth's Living Well expert, uses Vicks for her family. \"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children. Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options. Vicks is used topically on the skin, it's not ingested and is not included in these FDA guidelines.\"\nWhere's the line between research and marketing?\nShu says when used properly, Vicks appears to be safe. But as with any product, parents need to read the instructions carefully and keep medicines out of the reach of children. Vicks VapoRub is not recommend for children under the age of 2.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nAlthough, there\u2019s nothing new about VapoRub, the story does point out that the product claims have not been tested in this way before.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was correct in presenting the \"paint\" as a new possible adjunct to the methods used for determining tumor boundaries.", "answer": 1}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nSince then, the technique has been refined.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment makes clear that while this particular application of electrical stimulation is novel, it has been in development and used for other purposes for many years. ", "answer": 1}, {"article": "Nov. 14, 2011 -- The first use of heart stem cells in humans looks like a major breakthrough for people suffering heart failure after heart attacks.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the treatment is established. \n\n\n\nThe story does note that the technique is new and was developed by one of the researchers.", "answer": 1}, {"article": "According to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\" When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles. He is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story suggests that there is no clinically useful blood test to diagnose lung cancer currently available, and it implies the novelty of this test when it states that it builds on previous research. It also mentions that several other investigators are currently looking into blood tests for early-stage lung cancer.", "answer": 1}, {"article": "However, this has been shown to be false. Worse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nThat doesn\u2019t stop them from making them, or from them getting attention by mainstream media; attention they most assuredly do not deserve.\nIt\u2019s like Bizarro world, where everything is backward. All the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses. It also shows that the claims made by anti-vaxxers are wrong, and that people fighting the vaccine because of their own sexual biases are making things far worse.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the study driving the coverage is \u201cnew,\u201d but beyond that doesn\u2019t establish what is different or interesting about this research compared with previous studies.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story establish the true novelty of the approach?", "explanation": "No claims of novelty were made.", "answer": 2}, {"article": "March 11, 2010 (Miami Beach, Fla.) -- A moisturizing cream whose active ingredient is extract of onion can help take the redness out of new stretch marks. New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD. \"But [after several weeks of treatment], the cream made them look and feel better,\" she says. The study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology. Draelos has served as a consultant to Merz.\n\nDraelos estimates that up to 98% of women and 75% of men have stretch marks, which appear as wavy, linear red scars, typically on the hips, breasts, thighs, and stomach of women, and the buttocks and pectoralarea of men. They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt. Sinai Medical Center in New York City. He was not involved with the research. \"Unfortunately, stretch marks are permanent. Exercise and diet won't help,\" he says. They're not harmful to your health, but many people are bothered by their appearance. The marks slowly fade and become flat on their own, but that can take years. As a result, doctors have been looking for a product to make new stretch marks look and feel better, Draelos says.\n\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation. Onions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says. The new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says. And it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many creams that combine moisturizers and plant extracts and claim to treat skin problems.\u00a0This story should have challenged the notion that adding\u00a0onion extract to a skin\u00a0cream makes it\u00a0in any way \"new.\" \u00a0\u00a0\u00a0", "answer": 0}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins. Among the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nThe results don\u2019t settle the question of whether it\u2019s actually the vitamin pills that are protective, Rautiainen told Reuters Health via e-mail.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story accurately conveyed the lack of novelty of this treatment studied.", "answer": 1}]